

RC
268.5
U55
no. 43
1978

National Cancer Institute
CARCINOGENESIS
Technical Report Series
No. 43
1978

**BIOASSAY OF
EMETINE
FOR POSSIBLE CARCINOGENICITY**

CAS No. 483-18-1

NCI-CG-TR-43



U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service
National Institutes of Health

U.S. National Cancer Institute
"Carcinogenesis Technical Report Series"

BIOASSAY OF

EMETINE

FOR POSSIBLE CARCINOGENICITY

Carcinogenesis Testing Program
Division of Cancer Cause and Prevention
National Cancer Institute
National Institutes of Health
Bethesda, Maryland 20014

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service
National Institutes of Health

DHEW Publication No. (NIH) 78-843

RC

268.5

1155

11043

1978

BIOASSAY OF
EMETINE
FOR POSSIBLE CARCINOGENICITY

Carcinogenesis Testing Program
Division of Cancer Cause and Prevention
National Cancer Institute
National Institutes of Health

CONTRIBUTORS: This report presents the results of the bioassay of emetine for possible carcinogenicity, conducted for the Carcinogenesis Testing Program, Division of Cancer Cause and Prevention, National Cancer Institute (NCI), Bethesda, Maryland. The bioassay was conducted by Southern Research Institute, Birmingham, Alabama, initially under direct contract to NCI and currently under a subcontract to Tracor Jitco, Inc., prime contractor for the NCI Carcinogenesis Testing Program.

The experimental design and doses were determined by Drs. D. P. Griswold¹, J. D. Prejean¹, E. K. Weisburger², and J. H. Weisburger^{2,3}. Ms. J. Belzer¹ and Mr. I. Brown¹ were responsible for the care of the laboratory animals. Data management and retrieval were performed by Ms. C. A. Dominick¹. Histopathologic examinations were performed by Drs. S. D. Kosanke¹ and J. C. Peckham¹, and the diagnoses included in this report represent their interpretation. Reported neoplasms and treatment-related hyperplastic lesions were reviewed by Dr. J. F. Hardisty⁴, who also prepared the interpretive pathology summary included in this report.

Animal pathology tables and survival tables were compiled at EG&G Mason Research Institute⁵. The statistical analyses were performed by Dr. J. R. Joiner⁶, using methods selected for the bioassay program by Dr. J. J. Gart⁷. Chemicals used in this bioassay were analyzed by Drs. W. J. Morris⁸ and R. H. Iwamoto⁸, and the analytical results were reviewed by Dr. S. S. Olin⁶.

This report was prepared at Tracor Jitco⁶ under the direction of Dr. Marshall Steinberg, Director of the Bioassay Program; Drs. J.

F. Robens and C. H. Williams, toxicologists; Dr. R. L. Schueler, pathologist; Ms. M. S. King and Mr W. D. Reichardt, technical writers; and Dr. E. W. Gunberg, technical editor, assisted by Ms. Y. E. Presley and Ms. P. J. Graboske.

The statistical analysis was reviewed by one or more members of the Mathematical Statistics and Applied Mathematics Section of NCI⁷: Dr. John J. Gart, Mr. Jun-mo Nam, Dr. Hugh M. Pettigrew, and Dr. Robert E. Tarone.

The following other scientists at the National Cancer Institute were responsible for evaluating the bioassay experiment, interpreting the results, and reporting the findings:

Dr. Kenneth C. Chu
Dr. Cipriano Cueto, Jr.
Dr. J. Fielding Douglas
Dr. Dawn G. Goodman
Dr. Richard A. Griesemer
Mr. Harry A. Milman
Dr. Thomas W. Orme
Dr. Robert A. Squire⁹
Dr. Jerrold M. Ward

¹Southern Research Institute, 2000 Ninth Avenue South, Birmingham, Alabama.

²Carcinogenesis Testing Program, Division of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.

³Now with the Naylor Dana Institute for Disease Prevention, American Health Foundation, Hammond House Road, Valhalla, New York.

⁴Experimental Pathology Laboratories, 17 Pine Street, Herndon, Virginia.

⁵EG&G Mason Research Institute, 1530 East Jefferson Street,
Rockville, Maryland.

⁶Tracor Jitco, Inc., 1776 East Jefferson Street, Rockville,
Maryland.

⁷Mathematical Statistics and Applied Mathematics Section,
Biometry Branch, Field Studies and Statistics, Division of
Cancer Cause and Prevention, National Cancer Institute, National
Institutes of Health, Bethesda, Maryland.

⁸Stanford Research Institute, Menlo Park, California.

⁹Now with the Division of Comparative Medicine, Johns Hopkins
University, School of Medicine, Traylor Building, Baltimore,
Maryland.



SUMMARY

A bioassay of emetine, an amebicide and anticancer drug, for possible carcinogenicity was conducted by administering the test material by intraperitoneal injection to Sprague-Dawley rats and B6C3F1 mice.

Groups of 35 rats of each sex were administered emetine at one of two doses, either 0.5 or 1 mg/kg body weight, three times per week for 52 weeks, and then observed for an additional 31 or 32 weeks. Control groups of each sex consisted of 10 untreated rats (untreated controls) and 10 rats injected with buffered saline (vehicle controls). Pooled-control groups, used for statistical evaluation, consisted of the vehicle-control rats of each sex for this study combined with 15 vehicle-control rats of each sex from a similar bioassay of another test chemical. All surviving rats were killed at 83 or 84 weeks.

Initially, groups of 35 mice of each sex were administered emetine at one of two doses, either 3.2 or 6.4 mg/kg body weight (mid- and high-dose), three times per week. Control groups of each sex consisted of 15 untreated mice (untreated controls) and 15 mice injected with buffered saline (vehicle controls). Due to high mortality rates in the initial treated groups, additional groups of 35 mice of each sex were later put on study at 1.6 mg/kg (low-dose), together with 10 untreated-control and 10 vehicle-control mice of each sex. The high-dose males were treated for 28 weeks and the mid- and high-dose females for 40 and 33 weeks, respectively. Mid- and low-dose male mice and low-dose female mice were treated for 52 weeks, and then observed for an additional 20 or 26 weeks. All surviving mice were killed at 78-83 weeks.

Emetine was toxic to male rats at the high dose, to both sexes of mice at the high and mid doses and to a lesser extent at the low dose, as shown by the low survival in these groups. Twenty-six percent of the high-dose male rats and 69% of the high-dose female rats, but none of the high- and mid-dose mice of either sex, survived to the end of the study. In the low-dose mice,

30/35 males and 21/35 females lived at least 1 year, and the median time on study was 72 weeks for males and 59 weeks for females.

No tumors occurred at a statistically significant incidence in treated rats or mice compared with controls; however, it should be noted that in this study, treatment of both species was stopped at week 52 and the studies were terminated by week 83, which is earlier than in current bioassays where animals are treated until termination of the studies at 2 years. In addition, there was poor survival among the treated mice.

It is concluded that the results of this study do not allow evaluation of the possible carcinogenicity of emetine.

TABLE OF CONTENTS

	<u>Page</u>
I. Introduction.....	1
II. Materials and Methods.....	3
A. Chemical.....	3
B. Dosage Preparation.....	4
C. Animals.....	4
D. Animal Maintenance.....	5
E. Subchronic Studies.....	7
F. Designs of Chronic Studies.....	9
G. Clinical and Pathologic Examinations.....	9
H. Data Recording and Statistical Analyses.....	14
III. Results - Rats.....	19
A. Body Weights and Clinical Signs (Rats).....	19
B. Survival (Rats).....	19
C. Pathology (Rats).....	22
D. Statistical Analyses of Results (Rats).....	24
IV. Results - Mice.....	27
A. Body Weights and Clinical Signs (Mice).....	27
B. Survival (Mice).....	27
C. Pathology (Mice).....	33
D. Statistical Analyses of Results (Mice).....	34
V. Discussion.....	37
VI. Bibliography.....	39

APPENDIXES

Appendix A	Summary of the Incidence of Neoplasms in Rats Treated with Emetine.....	43
Table A1	Summary of the Incidence of Neoplasms in Male Rats Treated with Emetine.....	45
Table A2	Summary of the Incidence of Neoplasms in Female Rats Treated with Emetine.....	48

	<u>Page</u>
Appendix B	
Summary of the Incidence of Neoplasms in Mice Treated with Emetine.....	51
Table B1	
Summary of the Incidence of Neoplasms in Male Mice Treated with Emetine (Control Groups)....	53
Table B2	
Summary of the Incidence of Neoplasms in Male Mice Treated with Emetine (Treated Groups)....	56
Table B3	
Summary of the Incidence of Neoplasms in Female Mice Treated with Emetine (Control Groups)..	59
Table B4	
Summary of the Incidence of Neoplasms in Female Mice Treated with Emetine (Treated Groups)..	62
Appendix C	
Summary of the Incidence of Nonneoplastic Lesions in Rats Treated with Emetine.....	65
Table C1	
Summary of the Incidence of Nonneoplastic Lesions in Male Rats Treated with Emetine.....	67
Table C2	
Summary of the Incidence of Nonneoplastic Lesions in Female Rats Treated with Emetine.....	70
Appendix D	
Summary of the Incidence of Nonneoplastic Lesions in Mice Treated with Emetine.....	73
Table D1	
Summary of the Incidence of Nonneoplastic Lesions in Male Mice Treated with Emetine (Control Groups).....	75
Table D2	
Summary of the Incidence of Nonneoplastic Lesions in Male Mice Treated with Emetine (Treated Groups).....	78
Table D3	
Summary of the Incidence of Nonneoplastic Lesions in Female Mice Treated with Emetine (Control Groups).....	82
Table D4	
Summary of the Incidence of Nonneoplastic Lesions in Female Mice Treated with Emetine (Treated Groups).....	85
Appendix E	
Analyses of the Incidence of Primary Tumors in Rats Treated with Emetine.....	89


		<u>Page</u>
Table E1	Analyses of the Incidence of Primary Tumors in Male Rats Treated with Emetine.....	91
Table E2	Analyses of the Incidence of Primary Tumors in Female Rats Treated with Emetine.....	96
Appendix F	Analyses of the Incidence of Primary Tumors in Mice Treated with Emetine.....	101
Table F1	Analyses of the Incidence of Primary Tumors in Male Mice Treated with Emetine.....	103
Table F2	Time-adjusted Analyses of the Incidence of Primary Tumors in Male Mice Treated with Emetine...	105

TABLES

Table 1	Design of Chronic Studies of Emetine in Rats.....	10
Table 2	Design of Chronic Studies of Emetine in Male Mice.....	11
Table 3	Design of Chronic Studies of Emetine in Female Mice.....	12

FIGURES

Figure 1	Growth Curves for Rats Treated with Emetine.....	20
Figure 2	Survival Curves for Rats Treated with Emetine.....	21
Figure 3	Growth Curves for Male Mice Treated with Emetine.....	28
Figure 4	Growth Curves for Female Mice Treated with Emetine.....	29
Figure 5	Survival Curves for Male Mice Treated with Emetine.....	31
Figure 6	Survival Curves for Female Mice Treated with Emetine.....	32



I. INTRODUCTION

Emetine (CAS 483-18-1; NCI C01605), an alkaloid derived from the root of the tropical plant Cephaelis ipecacuanha, is used to treat severe amebic intestinal infections, amebic hepatitis, and amebic involvement of the lung, brain, skin, and other tissues (Rollo, 1975). Clinical symptoms of toxicity due to emetine include nausea, vomiting, diarrhea, muscle weakness, and cardiovascular disturbance.

In experimental studies, emetine was cytotoxic to transplantable mouse osteosarcoma in vitro but not in vivo (Morasca et al., 1974). In clinical studies, emetine was effective against non-specific granuloma (Grollman, 1966), and the analogue, dehydroemetine, was effective against leukemia, Hodgkin's disease, and rectal adenocarcinoma (Abd-Rabbo, 1966 and 1969; Wyburn-Mason, 1969). The drug has been shown to interfere with nucleic acid and protein biosynthesis in HeLa and other mammalian cells (Gilead and Becker, 1971; Grollman and Huang, 1973).

Emetine was tested in the carcinogenesis program in an attempt to evaluate the carcinogenicity of certain drugs that are used in humans over extended periods of time.

II. MATERIALS AND METHODS

A. Chemical

Emetine hydrochloride (6',7',10,11-tetramethoxyemetan dihydrochloride) was supplied by the Drug Development Branch, Division of Cancer Treatment (DCT), National Cancer Institute (NCI). The chemical was obtained in a single batch (Lot No. 988-0800) from Sigma Chemical Company, St. Louis, Missouri.

Analyses performed by Stanford Research Institute under contract to the Drug Development Branch, DCT, NCI, confirmed the identity and purity of this batch. Following United States Pharmacopeia (USP) assay procedures, the batch was found to contain 11.5% water, corresponding to a tetrahydrate, and approximately 1.5% cephaeline (a precursor in the synthesis). Less than 0.1% of one additional (unidentified) alkaloid was detected. These results conform to USP specifications. In addition, elemental analyses (C, H, N, Cl⁻) were correct for C₂₉H₄₀N₂O₄·2HCl·4H₂O, the molecular formula of emetine dihydrochloride tetrahydrate. Infra-red, ultraviolet, and nuclear magnetic resonance spectra also were as expected for emetine hydrochloride, hereinafter called emetine.

According to the USP, the chemical is affected by light. Stanford Research Institute reported noticeable decomposition (by

thin-layer chromatography) of an aqueous solution (ca. 25 mg/ml) after 1 week of exposure to ordinary illumination at room temperature. Therefore, solutions were prepared immediately before injection.

The bulk chemical was stored at -20°C.

B. Dosage Preparation

Buffered saline solution (pH 6.9) was used as the vehicle for intraperitoneal injection of the chemical. The drug and the vehicle were mixed in a 10-ml glass Potter-Elvehjem tissue grinder with a Teflon pestle. Fresh solutions were prepared daily and administered immediately. The concentrations were 0.02 and 0.04% for rats and 0.016, 0.032, and 0.064% for mice.

C. Animals

Sprague-Dawley rats and B6C3F1 mice of both sexes, obtained from Charles River Breeding Laboratories, Inc., Wilmington, Massachusetts, through contracts of the DCT, NCI, were used in this bioassay. On arrival at the laboratory, all animals were quarantined for an acclimation period (rats for 5 days, mice in the original study for 18 days, mice in the restarted study for 25 days), assigned to control and treated groups, and then earmarked for individual identification.

D. Animal Maintenance

All animals were housed in temperature- and humidity-controlled rooms. The temperature range was 20-24°C, and the relative humidity was maintained at 40-60%. The room air was changed 15 times per hour and passed through incoming and exhaust fiberglass roughing filters. In addition to natural light, illumination was provided by fluorescent light for 9 hours each day. Wayne® Lab Blox (Allied Mills, Inc., Chicago, Ill.) and water were supplied daily and were available ad libitum.

Rats were housed five per cage and mice seven per cage in solid-bottom stainless steel cages (Hahn Roofing and Sheet Metal Co., Birmingham, Ala.). The bottoms of the rat cages were lined with Iso-Dri® hardwood chips (Carworth, Edison, N.J.), and cage tops were covered with disposable filter bonnets beginning at week 18. Mouse cages were provided with Sterolit® clay bedding (Englehard Mineral and Chemical Co., New York, N.Y.). Cages of restarted groups of mice were provided with filter bonnets at week 75. Bedding was replaced once per week; cages, water bottles, feeders, and racks were sanitized once per week.

The rats and mice were housed in separate rooms. Control animals were housed with their respective treated animals. Animals treated with emetine were maintained in the same rooms as animals of the same species being treated with the following chemicals:

RATS

Gavage Studies

cholesterol (p-(bis(2-chloroethyl)amino)phenyl)acetate
(phenesterin) (CAS 3546-10-9)
estradiol bis((p-(bis(2-chloroethyl)amino)phenyl)acetate)
(estradiol mustard) (CAS 22966-79-6)

Intraperitoneal Injection Studies

4'-(9-acridinylamino)methansulfon-m-aniside monohydrochloride
(MAAM) (NSC 141549)
acronycine (CAS 7008-42-6)
5-azacytidine (CAS 320-67-2)
beta-2'-deoxy-6-thioguanosine monohydrate (beta-TGdR)
(CAS 789-61-7)
1,4-butanediol dimethanesulfonate (busulfan) (CAS 55-98-1)
3,3'-iminobis-1-propanol dimethanesulfonate (ester)
hydrochloride [IPD] (CAS 3458-22-8)
(+)-4,4'-(1-methyl-1,2-ethanediyl)bis-2,6-piperazinedione
(ICRF-159) (CAS 21416-87-5)
N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-
amine-2-oxide (isophosphamide) (CAS 3778-73-2)
N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine
hydrochloride (phenoxybenzamine) (CAS 63-92-3)
N-(1-methylethyl)-4-((2-methylhydrazino)methyl)benzamide
monohydrochloride (procarbazine) (CAS 366-70-1)
tris(1-aziridinyl)phosphine sulfide (thio-TEPA) (CAS 52-24-4)
2,4,6-tris(dimethylamino)-s-triazine (CAS 645-05-6)

MICE

Feed Studies

4-acetyl-N-((cyclohexylamino)carbonyl)benzenesulfonamide
(acetohexamide) (CAS 968-81-0)
anthranilic acid (CAS 118-92-3)
1-butyl-3-(p-tolylsulfonyl)urea (tolbutamide) (CAS 64-77-7)
4-chloro-N-((propylamino)carbonyl)benzenesulfonamide
(chlorpropamide) (CAS 94-20-2)
5-(4-chlorophenyl)-6-ethyl-2,4-pyrimidinediamine
(pyrimethamine) (CAS 58-14-0)
ethionamide (CAS 536-33-4)
2,6-diamino-3-(phenylazo)pyridine hydrochloride (phenazopyridine
hydrochloride) (CAS 136-40-3)
L-tryptophan (CAS 73-22-3)

N-9H-fluoren-2-ylacetamide (CAS 53-96-3)
N-(p-toluenesulfonyl)-N'-hexamethyleniminourea
(tolazamide) (CAS 1156-19-0)
1-phenethylbiguanide hydrochloride (phenformin) (CAS 114-86-3)
pyrazinecarboxamide (pyrazinamide) (CAS 98-96-4)
4,4'-sulfonyldianiline (dapsone) (CAS 80-08-0)
4,4'-thiodianiline (CAS 139-65-1)
ethionamide (CAS 536-33-4)

Gavage Studies

cholesterol (p-(bis(2-chloroethyl)amino)phenyl)acetate
(phenesterin) (CAS 3546-10-9)
estradiol bis((p-(bis(2-chloroethyl)amino)phenyl)acetate)
(estradiol mustard) (CAS 22966-79-6)

Intraperitoneal Injection Studies

4'-(9-acridinylamino)methansulfon-m-aniside monohydrochloride
(MAAM) (NSC 141549)
acronycine (CAS 7008-42-6)
5-azacytidine (CAS 320-67-2)
beta-2'-deoxy-6-thioguanosine monohydrate (beta-TGdR)
(CAS 789-61-7)
1,4-butanediol dimethanesulfonate (busulfan) (CAS 55-98-1)
3,3'-iminobis-1-propanol dimethanesulfonate (ester)
hydrochloride [IPD] (CAS 3458-22-8)
(+)-4,4'-(1-methyl-1,2-ethanediyl)bis-2,6-piperazinedione
(ICRF-159) (CAS 21416-87-5)
N,3-bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-
amine-2-oxide (isophosphamide) (CAS 3778-73-2)
N-(2-chloroethyl)-N-(1-methyl-2-phenoxyethyl)benzylamine
hydrochloride (phenoxybenzamine) (CAS 63-92-3)
N-(1-methylethyl)-4-((2-methylhydrazino)methyl)benzamide
monohydrochloride (procarbazine) (CAS 366-70-1)
tris(1-aziridinyl)phosphine sulfide (thio-TEPA) (CAS 52-24-4)
2,4,6-tris(dimethylamino)-s-triazine (CAS 645-05-6)

E. Subchronic Studies

Subchronic studies were conducted to estimate the maximum tolerated doses of emetine, on the basis of which low and high doses were determined for administration in the chronic studies.

In the subchronic studies, Sprague-Dawley male rats and Swiss male mice were administered emetine by intraperitoneal injection three times per week for 45 days. Following treatment, all animals were observed for an additional 45 days before termination of the study. Five animals of each species were used at each dose, and 10 animals of each species were used as untreated or vehicle (saline) controls.

In rats, administration of emetine at 0.1, 0.25, 0.5, and 1.0 mg/kg body weight resulted in no deaths and in no weight depression that exceeded the 15% guideline. At 2.0 mg/kg, the mean body weight was depressed and two animals died, one in week 7 and one in week 8. No lesions were observed in any of the animals. The low and high doses for rats were set at 0.5 and 1 mg/kg for the chronic studies.

In mice, the subchronic study was initially conducted at doses of 0.17, 0.43, 0.85, 1.7, and 3.4 mg/kg. No deaths attributable to drug toxicity and no weight depression exceeding the 15% guideline resulted. A second study was then performed using doses of 6.4, 12.8, and 25.6 mg/kg. Four of the five animals receiving 12.8 mg/kg died prior to week 6, and 4/5 animals receiving 25.6 mg/kg died prior to week 4; however, there were no deaths at 6.4 mg/kg. Weight depression did not exceed the 15% guideline in animals receiving 6.4 mg/kg, and no lesions were

seen in any of the animals at necropsy. The low and high doses for mice were set at 3.2 and 6.4 mg/kg for the chronic studies.

F. Designs of Chronic Studies

The designs of the chronic studies are shown in tables 1, 2, and 3.

Since the numbers of rats in the matched vehicle-control groups were small, pooled vehicle-control groups of rats also were used for statistical comparisons. Vehicle-control rats from the current injection studies on emetine were combined with vehicle-control rats from injection studies performed on 5-azacytidine (CAS 320-67-2). The pooled controls for statistical tests using rats consisted of 25 males and 25 females. The study on 5-azacytidine in rats was also conducted at Southern Research Institute and overlapped the emetine study by at least 17 months. The vehicle-control groups for 5-azacytidine were of the same strain and from the same suppliers, and they were examined by the same pathologists.

G. Clinical and Pathologic Examinations

All animals were observed twice daily for signs of toxicity, and animals that were moribund were killed and necropsied. Rats and mice were weighed individually every week for the first 2 months

Table 1. Design of Chronic Studies of Emetine in Rats

Sex and Treatment Group	Initial No. of Animals ^a	Emetine Dose ^b (mg/kg)	Time on Study	
			Treated ^c (weeks)	Untreated (weeks)
<u>Male</u>				
Untreated-Control	10	0		84
Vehicle-Control	10	0 ^d	52	32
Low-Dose	35	0.5	52	32
High-Dose	35	1	52	31
<u>Female</u>				
Untreated-Control	10	0		84
Vehicle-Control	10	0 ^d	52	32
Low-Dose	35	0.5	52	32
High-Dose	35	1	52	32

^aMale rats were 34 days of age and female rats were 41 days of age when placed on study.

^bEmetine was administered intraperitoneally in buffered saline three times per week at a volume of 0.25 ml/100 g body weight. Doses were based on individual weights.

^cAll rats were placed on study on the same day.

^dVehicle-control groups received buffered saline solution at the same volume as the treated groups.

Table 2. Design of Chronic Studies of Emetine in Male Mice

Sex and Treatment Group	Initial No. of Animals ^a	Emetine Dose ^b (mg/kg)	Time on Study	
			Treated (weeks)	Untreated (weeks)
Low-Dose Untreated-Control ^c	10	0		80
Low-Dose Vehicle-Control ^c	10	0 ^d	52	26
Low-Dose ^c	35	1.6	52	26
Mid- and High-Dose Untreated-Control	15	0		83
Mid- and High-Dose Vehicle-Control	15	0 ^d	52	30
Mid-Dose	35	3.2	52	20 ^e
High-Dose	35	6.4	28 ^f	

^aHigh- and mid-dose animals and their controls were 48 days of age when placed on study; low-dose animals and their controls were 58 days of age.

^bEmetine was administered intraperitoneally in buffered saline three times per week at a volume of 0.1 ml/10 g body weight. Doses were based on the mean weights of the animals in each cage.

^cDue to the high mortality of the treated animals, one additional low-dose group and two low-dose control groups were started 32 weeks after the original start of the study. The original low-dose group became the mid-dose group.

^dVehicle-control groups received buffered saline solution at the same volume as the treated groups.

^eAll mid-dose animals died or were killed by week 72.

^fAll high-dose animals died or were killed by week 28.

Table 3. Design of Chronic Studies of Emetine in Female Mice

Sex and Treatment Group	Initial No. of Animals ^a	Emetine Dose ^b (mg/kg)	Time on Study	
			Treated (weeks)	Untreated (weeks)
Low-Dose Untreated-Control ^c	10	0		80
Low-Dose Vehicle-Control ^c	10	0 ^d	52	27
Low-Dose ^c	35	1.6	52	26
Mid- and High-Dose Untreated-Control	15	0		83
Mid- and High-Dose Vehicle-Control	15	0 ^d	52	31
Mid-Dose	35	3.2	40 ^e	
High-Dose	35	6.4	33 ^f	

^aHigh- and mid-dose animals and their controls were 49 days of age when placed on study; low-dose animals and their controls were 58 days of age.

^bEmetine was administered intraperitoneally in buffered saline three times per week at a volume of 0.1 ml/10 g body weight. Doses were based on the mean weights of the animals in each cage.

^cDue to the high mortality of the treated animals, one additional low-dose group and two low-dose control groups were started 32 weeks after the original start of the study. The original low-dose group became the mid-dose group.

^dVehicle-control groups received buffered saline solution at the same volume as the treated groups.

^eAll mid-dose animals died or were killed by week 40.

^fAll high-dose animals died or were killed by week 33.

and every 2 weeks thereafter. Palpation for masses was carried out at each weighing.

The pathologic evaluation consisted of gross and microscopic examination of major tissues, major organs, and all gross lesions from killed animals and from animals found dead. The following tissues were examined microscopically: skin, muscle, lungs and bronchi, trachea, bone marrow, spleen, lymph nodes, thymus, heart, salivary gland, liver, gallbladder (mice), pancreas, esophagus, stomach, small intestine, large intestine, kidney, urinary bladder, pituitary, adrenal, thyroid, parathyroid, mammary gland, testis or ovary, prostate or uterus, brain, and sensory organs. Peripheral blood smears from each animal were prepared. Occasionally, additional tissues were also examined microscopically. The different tissues were preserved in 10% buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Special staining techniques were utilized when indicated for more definitive diagnosis.

A few tissues from some animals were not examined, particularly from those animals that died early. Also, some animals were missing, cannibalized, or judged to be in such an advanced state of autolysis as to preclude histopathologic evaluation. Thus, the number of animals from which particular organs or tissues were examined microscopically varies, and does not necessarily

represent the number of animals that were placed on study in each group.

H. Data Recording and Statistical Analyses

Pertinent data on this experiment have been recorded in an automatic data processing system, the Carcinogenesis Bioassay Data System (Linhart et al., 1974). The data elements include descriptive information on the chemicals, animals, experimental design, clinical observations, survival, body weight, and individual pathologic results, as recommended by the International Union Against Cancer (Berenblum, 1969). Data tables were generated for verification of data transcription and for statistical review.

These data were analyzed using the statistical techniques described in this section. Those analyses of the experimental results that bear on the possibility of carcinogenicity are discussed in the statistical narrative sections.

Probabilities of survival were estimated by the product-limit procedure of Kaplan and Meier (1958) and are presented in this report in the form of graphs. Animals were statistically censored as of the time that they died of other than natural causes or were found to be missing; animals dying from natural causes were not statistically censored. Statistical analyses for

a possible dose-related effect on survival used the method of Cox (1972) for testing two groups for equality and Tarone's (1975) extensions of Cox's methods for testing for a dose-related trend. One-tailed P values have been reported for all tests except the departure from linearity test, which is only reported when its two-tailed P value is less than 0.05.

The incidence of neoplastic or nonneoplastic lesions has been given as the ratio of the number of animals bearing such lesions at a specific anatomic site (numerator) to the number of animals in which that site is examined (denominator). In most instances, the denominators included only those animals for which that site was examined histologically. However, when macroscopic examination was required to detect lesions prior to histologic sampling (e.g., skin or mammary tumors), or when lesions could have appeared at multiple sites (e.g., lymphomas), the denominators consist of the numbers of animals necropsied.

The purpose of the statistical analyses of tumor incidence is to determine whether animals receiving the test chemical developed a significantly higher proportion of tumors than did the control animals. As a part of these analyses, the one-tailed Fisher exact test (Cox, 1970) was used to compare the tumor incidence of a control group with that of a group of treated animals at each dose level. When results for a number of treated groups (k) are

compared simultaneously with those for a control group, a correction to ensure an overall significance level of 0.05 may be made. The Bonferroni inequality (Miller, 1966) requires that the P value for any comparison be less than or equal to $0.05/k$. In cases where this correction was used, it is discussed in the narrative section. It is not, however, presented in the tables, where the Fisher exact P values are shown.

The Cochran-Armitage test for linear trend in proportions, with continuity correction (Armitage, 1971), was also used. Under the assumption of a linear trend, this test determines if the slope of the dose-response curve is different from zero at the one-tailed 0.05 level of significance. Unless otherwise noted, the direction of the significant trend is a positive dose relationship. This method also provides a two-tailed test of departure from linear trend.

A time-adjusted analysis was applied when numerous early deaths resulted from causes that were not associated with the formation of tumors. In this analysis, deaths that occurred before the first tumor was observed were excluded by basing the statistical tests on animals that survived at least 52 weeks, unless a tumor was found at the anatomic site of interest before week 52. When such an early tumor was found, comparisons were based exclusively on animals that survived at least as long as the animal in which

the first tumor was found. Once this reduced set of data was obtained, the standard procedures for analyses of the incidence of tumors (Fisher exact tests, Cochran-Armitage tests, etc.) were followed.

When appropriate, life-table methods were used to analyze the incidence of tumors. Curves of the proportions surviving without an observed tumor were computed as in Saffiotti et al. (1972). The week during which an animal died naturally or was sacrificed was entered as the time point of tumor observation. Cox's methods of comparing these curves were used for two groups; Tarone's extension to testing for linear trend was used for three groups. The statistical tests for the incidence of tumors which used life-table methods were one-tailed and, unless otherwise noted, in the direction of a positive dose relationship. Significant departures from linearity ($P < 0.05$, two-tailed test) were also noted.

The approximate 95 percent confidence interval for the relative risk of each treated group compared to its control was calculated from the exact interval on the odds ratio (Gart, 1971). The relative risk is defined as p_t/p_c where p_t is the true binomial probability of the incidence of a specific type of tumor in a treated group of animals and p_c is the true probability of the spontaneous incidence of the same type of tumor in a control

group. The hypothesis of equality between the true proportion of a specific tumor in a treated group and the proportion in a control group corresponds to a relative risk of unity. Values in excess of unity represent the condition of a larger proportion in the treated group than in the control.

The lower and upper limits of the confidence interval of the relative risk have been included in the tables of statistical analyses. The interpretation of the limits is that in approximately 95% of a large number of identical experiments, the true ratio of the risk in a treated group of animals to that in a control group would be within the interval calculated from the experiment. When the lower limit of the confidence interval is greater than one, it can be inferred that a statistically significant result ($P < 0.025$ one-tailed test when the control incidence is not zero, $P < 0.050$ when the control incidence is zero) has occurred. When the lower limit is less than unity, but the upper limit is greater than unity, the lower limit indicates the absence of a significant result while the upper limit indicates that there is a theoretical possibility of the induction of tumors by the test chemical, which could not be detected under the conditions of this test.

III. RESULTS - RATS

A. Body Weights and Clinical Signs (Rats)

Body weights of the low-dose male rats were comparable to those of both the untreated and vehicle controls (figure 1). The weights of the high-dose males were lower than those of the controls during the period in which emetine was administered, but were similar after treatment was discontinued. The high-dose female rats had lower body weights than those of both the control groups, while the body weights of the low-dose female rats were lower than those of the untreated controls, but similar to those of the vehicle controls. Fluctuations in the growth curve may be due to mortality; as the size of the group diminishes, the mean body weight may be subject to wide variation.

No other clinical signs clearly associated with the administration of emetine were recorded.

B. Survival (Rats)

The Kaplan and Meier curves estimating the probabilities of survival for male and female rats administered emetine by intraperitoneal injection at the doses used in this experiment, together with those of the matched controls, are shown in figure 2.





Figure 1. Growth Curves For Rats Treated With Emetine





Figure 2. Survival Curves for Rats Treated With Emetine

In male rats, the Tarone test result for positive dose-related trend in mortality is significant ($P < 0.001$), and an indicated departure from linear trend is observed ($P < 0.001$), due to the steep increase in mortality in the high-dose rats, of which only 26% lived to the end of the study, with a median time on study of 53 weeks. Of the high-dose male rats, 18/35 lived at least 52 weeks on study, and no tumor was observed before this time. At least 80% of the low-dose, vehicle-control, and untreated-control groups survived to the end of the study.

In female rats, the Tarone test result is not significant; 69% of the high-dose group, 83% of the low-dose group, all of the vehicle-control group, and 70% of the untreated-control group survived to termination of the study, providing sufficient numbers of treated female rats for development of late-appearing tumors.

C. Pathology (Rats)

Histopathologic findings on neoplasms in rats are summarized in Appendix A, tables A1 and A2; findings on nonneoplastic lesions are summarized in Appendix C, tables C1 and C2.

A variety of neoplasms were seen both in control and treated rats. Neoplasms were seen more frequently in the females than in the males. The most frequently observed neoplasms in the female

rats were chromophobe adenomas of the pituitary gland, cortical adenomas of the adrenal gland, and fibroadenomas of the mammary gland. The neoplasms of the pituitary and adrenal glands occurred with approximately equal frequency in treated and control rats. The incidence of fibroadenomas of the mammary gland was higher in the treated female rats than in the controls. These tumors were characterized by local proliferations of well-differentiated fibrous tissue surrounding proliferating mammary acinar and ductular epithelium. Much structural variation was present in these neoplasms. In some of the neoplasms, the connective tissue stroma was predominant, and in others, there was a marked epithelial overgrowth. The histologic appearance of the neoplasms in both the treated and control female rats was similar to fibroadenomas known to occur spontaneously in female Sprague-Dawley rats. Although the incidence of the neoplasm was higher in the treated rats than in the controls, it was comparable to published reports of spontaneously occurring mammary gland fibroadenomas in this strain of rat (Davis et al., 1959; Prejean et al., 1973; Thompson et al., 1961).

A variety of inflammatory, degenerative, and proliferative lesions commonly seen in aged Sprague-Dawley rats were observed with approximately equal frequency in treated and control animals. Although there was a higher incidence of spontaneous

deaths in the treated groups, there were no consistent neoplastic or nonneoplastic lesions in the animals that died spontaneously.

There were instances in this study where neoplastic lesions occurred only in treated animals, or with increased frequency when compared with the control group. The nature and incidence of these lesions were similar to those known to occur spontaneously in aged Sprague-Dawley rats. The histopathologic evaluation of the study indicated that emetine administered for the time period and at the doses used in this study did not induce neoplastic lesions in the Sprague-Dawley rat.

D. Statistical Analyses of Results (Rats)

Tables E1 and E2 in Appendix E contain the statistical analyses of the incidences of those primary tumors that were observed in at least 5% of a treated group. The untreated controls are not included in these tables and analyses, since the experimental conditions of the vehicle controls more closely resemble those of the treated animals.

In both sexes, the results of the Cochran-Armitage test for positive dose-related trend and the Fisher exact test for direct comparison of incidences between each of the control groups and each of the treated groups are not significant.

In female rats the Cochran-Armitage test and the incidence of cortical adenoma of the adrenal gland using pooled controls indicate a significant trend in the negative direction, but this negative trend is not substantiated by the Fisher exact test. Furthermore, the life-table-adjusted test for the incidence of cortical adenoma does not show a significant negative trend.

In each of the 95% confidence intervals of relative risk, shown in the tables, the value of one is included, indicating the absence of positive significant results. It should also be noted that each of the intervals has an upper limit greater than one, indicating the theoretical possibility of the induction of tumors by emetine, which could not be detected under the conditions of this test.



IV. RESULTS - MICE

A. Body Weights and Clinical Signs (Mice)

The high-dose male and female mice gained little weight, and most of these animals died by week 33 (figures 3 and 4). The mean body weights of the male mid-dose mice were lower than those of both the control groups, while those of the female mid-dose mice were comparable to those of the vehicle controls during the 40 weeks these mice survived. Mean body weights of the low-dose groups of both sexes were comparable to those of both the control groups.

Emetine was sufficiently toxic at the mid dose and high dose to cause a shortened life span. No clinical signs of toxicity were reported for the low-dose groups.

To control respiratory disease, the initial groups of mice were treated with oxytetracycline in the drinking water at doses of 0.6 mg/ml for 5 days during week 55, followed by treatment for 5 days at 0.3 mg/ml. The restarted groups were not treated with oxytetracycline.

B. Survival (Mice)

The Kaplan and Meier curves estimating the probabilities of survival for male and female mice administered emetine by





Figure 3. Growth Curves For Male Mice Treated With Emetine






Figure 4. Growth Curves For Female Mice Treated With Emetine

intraperitoneal injection at the doses used in this experiment, together with those of the matched controls, are shown in figures 5 and 6.

In both sexes, the Tarone test results for positive dose-related trend in mortality are significant ($P < 0.001$), and an indicated departure from linear trend is observed ($P < 0.001$), due to the steep increase in mortality in the high- and mid-dose mice. In male mice, none of the high- and mid-dose groups, but 41% of the low-dose group and at least 78% of the controls, lived to the end of the study. The median times on study for the high-, mid-, and low-dose male mice were 21 weeks, 30 weeks, and 72 weeks, respectively. Only 1/35 high-dose and 2/35 mid-dose male mice lived beyond week 52 on study; no tumor was observed in these two groups of mice. Thirty of 35 low-dose male mice survived beyond week 52, but one tumor (hepatocellular carcinoma) was found as early as week 50 on study. Time-adjusted analyses were also performed, eliminating animals that died before week 52 on study. Since one hepatocellular carcinoma occurred at week 50, the time-adjusted analysis of this particular incidence is based on animals that lived at least as long as week 50 on study.

In female mice, none of the high- and mid-dose groups, but 31% of the low-dose group, at least 60% of the vehicle controls, and at least 80% of the untreated controls lived to the end of the






Figure 6. Survival Curves For Female Mice Treated With Emetine

study. The median times on study of the high-, mid-, and low-dose female mice were 25 weeks, 23 weeks, and 59 weeks, respectively. All of the high- and mid-dose female mice died before week 52 on study. No tumor was observed in the mid-dose group, but one alveolar/bronchiolar adenoma was found in the high-dose group as early as week 21. Of the low-dose female mice, 21/35 lived to at least week 52; no tumor was observed before that time.

The early deaths of the treated mice of both sexes may have affected the incidences of late-appearing tumors.

C. Pathology (Mice)

Histopathologic findings on neoplasms in mice are summarized in Appendix B, tables B1-B4; findings on nonneoplastic lesions are summarized in Appendix D, tables D1-D4.

A variety of neoplasms occurred with approximately equal frequency in control and treated mice. There was a low incidence of neoplasia in both control and treated mice. The extremely low incidence of neoplasia in the mid- and high-dose mice was probably due to the high number of early deaths that occurred in these groups.

Several inflammatory and degenerative lesions occurred with approximately equal frequency in the control and treated mice. The treated groups had a higher incidence of inflammatory lesions in the respiratory system, the digestive system, and the abdominal cavity when compared with the control groups. These inflammatory lesions appeared to be related to emetine at these doses and associated with an increase in mortality.

•

The histopathologic evaluation of the lesions indicated that emetine administered for the time period and at the doses used in this study had a toxic effect, since the higher doses caused a shortened life span.

D. Statistical Analyses of Results (Mice)

Tables F1 and F2 in Appendix F contain the statistical analyses of the incidences of those primary tumors that were observed in at least 5% of a treated group. The untreated controls are not included in these tables and analyses, since the experimental conditions of the vehicle controls more closely resemble those of the treated groups. There is no table or analysis for female mice, because the proportions of lesions in the treated groups are less than 5%. In fact, only three tumors were observed among all treated female mice: two in the low-dose and one in the high-dose group.

Since there was extremely high mortality in the treated male mice, time-adjusted analyses were performed, eliminating animals that died before week 52 on study. One hepatocellular carcinoma was found as early as week 50 in the low-dose group; thus, the time-adjusted analysis of the incidence of this tumor of the liver is based only on animals that lived at least as long as week 50 on study. These time-adjusted analyses of the male mice are shown in table F2 in Appendix F.

The Cochran-Armitage test is not applied here, because the survivals of the various treated and control groups are not comparable. The Fisher exact test for direct comparison of the incidences in each of the control groups with those in each of the treated groups are not significant, either before or after the time-adjustment. In each of the 95% confidence intervals of relative risk, shown in the tables, the value of one is included, indicating the absence of positive significant results. It should also be noted that each of the intervals has an upper limit greater than one, indicating the theoretical possibility of the induction of tumors by emetine, which could not be detected under the conditons of this test.

100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200

V. DISCUSSION

In this bioassay, emetine was toxic to male rats at the high dose, to both sexes of mice at the high and mid doses, and to a lesser extent at the low dose, as shown by the low survival in these groups. This study was terminated at week 84 in rats and week 83 in mice. Twenty-six percent of the high-dose male rats and 69% of the high-dose female rats survived to the end of the study. In mice, none of the high- and mid-dose animals of either sex survived to the end of the study. At the low-dose, 30/35 males and 21/35 females lived for at least 1 year, and the median time on study was 72 weeks for the males and 59 weeks for the females.

A variety of neoplasms were observed in both control and treated rats, but only the incidence of fibroadenoma of the mammary gland in the females was higher in the treated rats than in the controls. However, the incidence was not statistically significant.

The incidences of neoplasms in treated mice of each sex were low and were similar to those of both untreated and vehicle controls.

As early as 1912, the use of emetine in the chemotherapy of amebiasis was recorded, and reports of its antitumor activity appeared as early as 1918 and 1919 (Grollman and Jarkovsky,

1975). The results of a 24-week test for the carcinogenicity of emetine in mice, evaluated by measuring the induction of pulmonary tumors, was negative (Stoner et al., 1973).

It should be noted that in this study, treatment of both species was stopped at week 52 and the studies were terminated by week 83, which is earlier than in current bioassays where animals are treated until termination of the studies at 2 years. In addition, there was poor survival among the treated mice.

It is concluded that the results of this study do not allow evaluation of the possible carcinogenicity of emetine.

VI. BIBLIOGRAPHY

✓ Abd-Rabbo, H., Chemotherapy of neoplasia (cancer) with dehydroemetine. J. Trop. Med. Hyg. 72(12):287-290, 1969.

✓ Abd-Rabbo, H., Dehydroemetine in chronic leukemia. Lancet 1:1161-162, 1966.

Armitage, P., Statistical Methods in Medical Research, John Wiley & Sons, Inc., 1971, pp. 362-365.

Berenblum, I., ed., Carcinogenicity Testing: A Report of the Panel on Carcinogenicity of the Cancer Research Commission of the UICC, International Union Against Cancer, Geneva, 1969.

Cox, D. R., Regression models and life tables. J. R. Statist. Soc. B 34(2):187-220, 1972.

Cox, D. R., Analysis of Binary Data, Methuen & Co., Ltd., London, 1970, pp. 48-52.

Davis, R. K., Stevenson, G. T., and Busch, K. A., Tumor incidence in normal Sprague-Dawley female rats. Cancer Res. 16:194-197, 1959.

Gart, J. J., The comparison of proportions: a review of significance tests, confidence limits and adjustments for stratification. Rev. Int. Statist. Inst. 39:148-169, 1971.

✓ Gilead, Z. and Becker, Y., Effect of emetine on ribonucleic acid biosynthesis in HeLa cells. Eur. J. Biochem. 23:143-149, 1971.

✓ Grollman, A. P. and Jarkovsky, Z., Emetine and related alkaloids. In: Antibiotics, Vol. III: Mechanism of Action of Antimicrobial and Antitumor Agents, eds., Corcoran, J. W. and Hahn, F. E., Springer-Verlag, New York, 1975, pp. 420-435.

✓ Grollman, A. P. and Huang, M. T., Inhibitors of protein synthesis in eukaryotes: tools in cell research. Federation Proc. 32:1673-1678, 1973.

- Grollman, A. P., Structural basis for inhibition of protein synthesis by emetine and cycloheximide based on an analogy between ipecac alkaloids and glutarimide antibiotics. Proc. Natl. Acad. Sci., USA 56:1867-1874, 1966.
- Kaplan, E. L. and Meier, P., Nonparametric estimation from incomplete observations. J. Amer. Statist. Assoc. 53:457-481, 1958.
- Linhart, M. S., Cooper, J., Martin, R. L., Page, N., and Peters, J., Carcinogenesis bioassay data system. Comp. and Biomed. Res. 7:230-248, 1974.
- Miller, R. G., Jr., Simultaneous Statistical Inference, McGraw-Hill Book Co., New York, 1966, pp. 6-10.
- Morasca, L., Balconi, G., Erba, E., Lilieveld, P. and van Putten, L. M., Cytotoxic effect in vitro and tumour volume reduction in vivo induced by chemotherapeutic agents. Eur. J. Cancer 10(10):667-671, 1974.
- Prejean, J. D., Peckham, J. C., Casey, A. E., Greswald, D. P., Weisburger, E. K., and Weisburger, J. H., Spontaneous tumors in Sprague-Dawley rats and Swiss mice. Cancer Res. 33:2768-2773, 1973.
- Rollo, I. M., Drugs used in the chemotherapy of amebiasis. In: The Pharmacological Basis of Therapeutics, eds., Goodman, L. S. and Gilman, A., MacMillan, New York, 1975, pp. 1069-1080.
- Saffiotti, U., Montesano, R., Sellakumar, A. R., Cefis, F., and Kaufman, D. G., Respiratory tract carcinogenesis in hamsters induced by different numbers of administrations of benzo(a) pyrene and ferric oxide. Cancer Res. 32:1073-1081, 1972.
- Stoner, G. D., Shimkin, M. B., Kniazeff, A. J., Weisburger, J. H., Weisburger, E. K., and Gori, G. B., Test for carcinogenicity of food additives and chemotherapeutic agents by the pulmonary tumor response in strain A mice. Cancer Res. 33:3069-3085, 1973.
- Tarone, R. E., Tests for trend in life table analysis. Biometrika 62(3):679-682, 1975.

Thompson, S. W., Husby, R. A., Fox, M. A., Davis, C. L., and
Hunt, R. D., Spontaneous tumors in the Sprague-Dawley rat.
J. Natl. Cancer Inst. 27:1037-1057, 1961.

✓ Wyburn-Mason, R., Dehydroemetine in chronic leukemia. Lancet
I:1266-1267, 1966.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

APPENDIX A

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN
RATS TREATED WITH EMETINE

1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
2220
2221
2222
2223
2224
2225
2226
2227
2228
2229
2230
2231
2232
2233
2234
2235
2236
2237
2238
2239
2240
2241
2242
2243
2244
2245
2246
2247
2248
2249
2250
2251
2252
2253
2254
2255
2256
2257
2258
2259
2260
2261
2262
2263
2264
2265
2266
2267
2268
2269
2270
2271
2272
2273
2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285
2286
2287
2288
2289
2290
2291
2292
2293
2294
2295
2296
2297
2298
2299
2300
2301
2302
2303
2304
2305
2306
2307
2308
2309
2310
2311
2312
2313
2314
2315
2316
2317
2318
2319
2320
2321
2322
2323
2324
2325
2326
2327
2328
2329
2330
2331
2332
2333
2334
2335
2336
2337
2338
2339
2340
2341
2342
2343
2344
2345
2346
2347
2348
2349
2350
2351
2352
2353
2354
2355
2356
2357
2358
2359
2360
2361
2362
2363
2364
2365
2366
2367
2368
2369
2370
2371
2372
2373
2374
2375
2376
2377
2378
2379
2380
2381
2382
2383
2384
2385
2386
2387
2388
2389
2390
2391
2392
2393
2394
2395
2396
2397
2398
2399
2400
2401
2402
2403
2404
2405
2406
2407
2408
2409
2410
2411
2412
2413
2414
2415
2416
2417
2418
2419
2420
2421
2422
2423
2424
2425
2426
2427
2428
2429
2430
2431
2432
2433
2434
2435
2436
2437
2438
2439
2440
2441
2442
2443
2444
2445
2446
2447
2448
2449
2450
2451
2452
2453
2454
2455
2456
2457
2458
2459
2460
2461
2462
2463
2464
2465
2466
2467
2468
2469
2470
2471
2472
2473
2474
2475
2476
2477
2478
2479
2480
2481
2482
2483
2484
2485
2486
2487
2488
2489
2490
2491
2492
2493
2494
2495
2496
2497
2498
2499
2500
2501
2502
2503
2504
2505
2506
2507
2508
2509
2510
2511
2512
2513
2514
2515
2516
2517
2518
2519
2520
2521
2522
2523
2524
2525
2526
2527
2528
2529
2530
2531
2532
2533
2534
2535
2536
2537
2538
2539
2540
2541
2542
2543
2544
2545
2546
2547
2548
2549
2550
2551
2552
2553
2554
2555
2556
2557
2558
2559
2560
2561
2562
2563
2564
2565
2566
2567
2568
2569
2570
2571
2572
2573
2574
2575
2576
2577
2578
2579
2580
2581
2582
2583
2584
2585
2586
2587
2588
2589
2590
2591
2592
2593
2594
2595
2596
2597
2598
2599
2600
2601
2602
2603
2604
2605
2606
2607
2608
2609
2610
2611
2612
2613
2614
2615
2616
2617
2618
2619
2620
2621
2622
2623
2624
2625
2626
2627
2628
2629
2630
2631
2632
2633
2634
2635
2636
2637
2638
2639
2640
2641
2642
2643
2644
2645
2646
2647
2648
2649
2650
2651
2652
2653
2654
2655
2656
2657
2658
2659
2660
2661
2662
2663
2664
2665
2666
2667
2668
2669
2670
2671
2672
2673
2674
2675
2676
2677
2678
2679
2680
2681
2682
2683
2684
2685
2686
2687
2688
2689
2690
2691
2692
2693
2694
2695
2696
2697
2698
2699
2700
2701
2702
2703
2704
2705
2706
2707
2708
2709
2710
2711
2712
2713
2714
2715
2716
2717
2718
2719
2720
2721
2722
2723
2724
2725
2726
2727
2728
2729
2730
2731
2732
2733
2734
2735
2736
2737
2738
2739
2740
2741
2742
2743
2744
2745
2746
2747
2748
2749
2750
2751
2752
2753
2754
2755
2756
2757
2758
2759
2760
2761
2762
2763
2764
2765
2766
2767
2768
2769
2770
2771
2772
2773
2774
2775
2776
2777
2778
2779
2780
2781
2782
2783
2784
2785
2786
2787
2788
2789
2790
2791
2792
2793
2794
2795
2796
2797
2798
2799
2800
2801
2802
2803
2804
2805
2806
2807
2808
2809
2810
2811
2812
2813
2814
2815
2816
2817
2818
2819
2820
2821
2822
2823
2824
2825
2826
2827
2828
2829
2830
2831
2832
2833
2834
2835
2836
2837
2838
2839
2840
2841
2842
2843
2844
2845
2846
2847
2848
2849
2850
2851
2852
2853
2854
2855
2856
2857
2858
2859
2860
2861
2862
2863
2864
2865
2866
2867
2868
2869
2870
2871
2872
2873
2874
2875
2876
2877
2878
2879
2880
2881
2882
2883
2884
2885
2886
2887
2888
2889
2890
2891
2892
2893
2894
2895
2896
2897
2898
2899
2900
2901
2902
2903
2904
2905
2906
2907
2908
2909
2910
2911
2912
2913
2914
2915
2916
2917
2918
2919
2920
2921
2922
2923
2924
2925
2926
2927
2928
2929
2930
2931
2932
2933
2934
2935
2936
2937
2938
2939
2940
2941
2942
2943
2944
2945
2946
2947
2948
2949
2950
2951
2952
2953
2954
2955
2956
2957
2958
2959
2960
2961
2962
2963
2964
2965
2966
2967
2968
2969
2970
2971
2972
2973
2974
2975
2976
2977
2978
2979
2980
2981
2982
2983
2984
2985
2986
2987
2988
2989
2990
2991
2992
2993
2994
2995
2996
2997
2998
2999
3000
3001
3002
3003
3004
3005
3006
3007
3008
3009
3010
3011
3012
3013
3014
3015
3016
3017
3018
3019
3020
3021
3022
3023
3024
3025
3026
3027
3028
3029
3030
3031
3032
3033
3034
3035
3036
3037
3038
3039
3040
3041
3042
3043
3044
3045
3046
3047
3048
3049
3050
3051
3052
3053
3054
3055
3056
3057
3058
3059
3060
3061
3062
3063
3064
3065
3066
3067
3068
3069
3070
3071
3072
3073
3074
3075
3076
3077
3078
3079
3080
3081
3082
3083
3084
3085
3086
3087
3088
3089
3090
3091
3092
3093
3094
3095
3096
3097
3098
3099
3100
3101
3102
3103
3104
3105
3106
3107
3108
3109
3110
3111
3112
3113
3114
3115
3116
3117
3118
3119
3120
3121
3122
3123
3124
3125
3126
3127
3128
3129
3130
3131
3132
3133
3134
3135
3136
3137
3138
3139
3140
3141
3142
3143
3144
3145
3146
3147
3148
3149
3150
3151
3152
3153
3154
3155
3156
3157
3158
3159
3160
3161
3162
3163
3164
3165
3166
3167
3168
3169
3170
3171
3172
3173
3174
3175
3176
3177
3178
3179
3180
3181
3182
3183
3184
3185
3186
3187
3188
3189
3190
3191
3192
3193
3194
3195
3196
3197
3198
3199
3200
3201
3202
3203
3204
3205
3206
3207
3208
3209
3210
3211
3212
3213
3214
3215
3216
3217
3218
3219
3220
3221
3222
3223
3224
3225
3226
3227
3228
3229
3230
3231
3232
3233
3234
3235
3236
3237
3238
3239
3240
3241
3242
3243
3244
3245
3246
3247
3248
3249
3250
3251
3252
3253
3254
3255
3256
3257
3258
3259
3260
3261
3262
3263
3264
3265
3266
3267
3268
3269
3270
3271
3272
3273
3274
3275
3276
3277
3278
3279
3280
3281
3282
3283
3284
3285
3286
3287
3288
3289
3290
3291
3292
3293
3294
3295
3296
3297
3298
3299
3300
3301
3302
3303
3304
3305
3306
3307
3308
3309
3310
3311
3312
3313
3314
3315
3316
3317
3318
3319
3320
3321
3322
3323
3324
3325
3326
3327
3328
3329
3330
3331
3332
3333
3334
3335
3336
3337
3338
3339
3340
3341
3342
3343
3344
3345
3346
3347
3348
3349
3350
3351
3352
3353
3354
3355
3356
3357
3358
3359
3360
3361
3362
3363
3364
3365
3366
3367
3368
3369
3370
3371
3372
3373
3374
3375
3376
3377
3378
3379
3380
3381
3382
3383
3384
3385
3386
3387
3388
3389
3390
3391
3392
3393
3394
3395
3396
3397
3398
3399
3400
3401
3402
3403
3404
3405
3406
3407
3408
3409
3410
3411
3412
3413
3414
3415
3416
3417
3418
3419
3420
3421
3422
3423
3424
3425
3426
3427
3428
3429
3430
3431
3432
3433
3434
3435
3436
3437
3438
3439
3440
3441
3442
3443
3444
3445
3446
3447
3448
3449
3450
3451
3452
3453
3454
3455
3456
3457
3458
3459
3460
3461
3462
3463
3464
3465
3466
3467
3468
3469
3470
3471
3472
3473
3474
3475
3476
3477
3478
3479
3480
3481
3482
3483
3484
3485
3486
3487
3488
3489
3490
3491
3492
3493
3494
3495
3496
3497
3498
3499
3500
3501
3502
3503
3504
3505
3506
3507
3508
3509
3510
3511
3512
3513
3514
3515
3516
3517
3518
3519
3520
3521
3522
3523
3524
3525
3526
3527
3528
3529
3530
3531
3532
3533
3534
3535
3536
3537
3538
3539
3540
3541
3542
3543
3544
3545
3546
3547
3548
3549
3550
3551
3552
3553
3554
3555
3556
3557
3558
3559
3560
3561
3562
3563
3564
3565
3566
3567
3568
3569
3570
3571
3572
3573
3574
3575
3576
3577
3578
3579
3580
3581
3582
3583
3584
3585
3586
3587
3588
3589
3590
3591
3592
3593
3594
3595
3596
3597
3598
3599
3600
3601
3602
3603
3604
3605
3606
3607
3608
3609
3610
3611
3612
3613
3614
3615
3616
3617
3618
3619
3620
3621
3622
3623
3624
3625
3626
3627
3628
3629
3630
3631
3632
3633
3634
3635
3636
3637
3638
3639
3640
3641
3642
3643
3644
3645
3646
3647
3648
3649
3650
3651
3652
3653
3654
3655
3656
3657
3658
3659
3660
3661
3662
3663
3664
3665
3666
3667
3668
3669
3670
3671
3672
3673
3674
3675
3676
3677
3678
3679
3680
3681
3682
3683
3684
3685
3686
3687
3688
3689
3690
3691
3692
3693
3694
3695
3696
3697
3698
3699
3700
3701
3702
3703
3704
3705
3706
3707
3708
3709
3710
3711
3712
3713
3714
3715
3716
3717
3718
3719
3720
3721
3722
3723
3724
3725
3726
3727
3728
3729
3730
3731
3732
3733
3734
3735
3736
3737
3738
3739
3740
3741
3742
3743
3744
3745
3746
3747
3748
3749
3750
3751
3752
3753
3754
3755
3756
3757
3758
3759
3760
3761
3762
3763
3764
3765
3766
3767
3768
3769
3770
3771
3772
3773
3774
3775
3776
3777
3778
3779
3780
3781
3782
3783
3784
3785
3786
3787
3788
3789
3790
3791
3792
3793
3794
3795
3796
3797
3798
3799
3800
3801
3802
3803
3804
3805
3806
3807
3808
3809
3810
3811
3812
3813
3814
3815
3816
3817
3818
3819
3820
3821
3822
3823
3824
3825
3826
3827
3828
3829
3830
3831
3832
3833
3834
3835
3836
3837
3838
3839
3840
3841
3842
3843
3844
3845
3846
3847
3848
3849
3850
3851
3852
3853
3854
3855
3856
3857
3858
3859
3860
3861
3862
3863
3864
3865
3866
3867
3868
3869
3870
3871
3872
3873
3874
3875
3876
3877
3878
3879
3880
3881
3882
3883
3884
3885
3886
3887
3888
3889
3890
3891
3892
3893
3894
3895
3896
3897
3898
3899
3900
3901
3902
3903
3904
3905
3906
3907
3908
3909
3910
3911
3912
3913
3914
3915
3916
3917
3918
3919
3920
3921
3922
3923
3924
3925
3926
3927
3928
3929
3930
3931
3932
3933
3934
3935

TABLE A1.

**SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS
TREATED WITH EMETINE**

	UNTREATED CONTROL	VEHICLE CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	10	10	35	35
ANIMALS NECROPSIED	10	10	35	27
ANIMALS EXAMINED HISTOPATHOLOGICALLY	10	10	35	27
INTEGUMENTARY SYSTEM				
*SKIN	(10)	(10)	(35)	(27)
SQUAMOUS CELL PAPILLOMA			1 (3%)	
*SUBCUT TISSUE	(10)	(10)	(35)	(27)
FIBROMA			2 (6%)	
LIPOMA			1 (3%)	
LEIOMYOSARCOMA			1 (3%)	
RESPIRATORY SYSTEM				
NONE				
HEMATOPOIETIC SYSTEM				
NONE				
CIRCULATORY SYSTEM				
NONE				
DIGESTIVE SYSTEM				
*LIVER	(10)	(10)	(35)	(27)
HEPATOCELLULAR ADENOMA			2 (6%)	
*STOMACH	(10)	(10)	(35)	(27)
FIBROSARCOMA				1 (4%)
URINARY SYSTEM				
NONE				
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)

	UNTREATED CONTROL	VEHICLE CONTROL	LOW DOSE	HIGH DOSE
ENDOCRINE SYSTEM				
*PITUITARY	(10)	(10)	(32)	(22)
CHROMOPHOBE ADENOMA	1 (10%)	1 (10%)	3 (9%)	1 (5%)
CHROMOPHOBE CARCINOMA	2 (20%)	1 (10%)	1 (3%)	1 (5%)
*ADRENAL	(9)	(10)	(35)	(27)
CORTICAL ADENOMA			1 (3%)	
PHEOCHROMOCYTOMA		1 (10%)	1 (3%)	
*PARATHYROID	(8)	(4)	(10)	(7)
ADENOMA, NOS				1 (14%)
*PANCREATIC ISLETS	(10)	(9)	(34)	(26)
ISLET-CELL ADENOMA			2 (6%)	1 (4%)
REPRODUCTIVE SYSTEM				
*MAMMARY GLAND	(10)	(10)	(35)	(27)
FIBROADENOMA				1 (4%)
*TESTIS	(9)	(10)	(34)	(27)
INTERSTITIAL-CELL TUMOR			3 (9%)	
NERVOUS SYSTEM				
NONE				
SPECIAL SENSE ORGANS				
NONE				
MUSCULOSKELETAL SYSTEM				
NONE				
BODY CAVITIES				
NONE				
ALL OTHER SYSTEMS				
NONE				
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)

	UNTREATED CONTROL	VEHICLE CONTROL	LOW DOSE	HIGH DOSE
ANIMAL DISPOSITION SUMMARY				
ANIMALS INITIALLY IN STUDY	10	10	35	35
NATURAL DEATH [ⓓ]	2	1	1	15
MORIBUND SACRIFICE			2	11
SCHEDULED SACRIFICE				
ACCIDENTALLY KILLED			1	
TERMINAL SACRIFICE	8	9	31	9
ANIMAL MISSING				
ⓓ INCLUDES AUTOLYZED ANIMALS				
TUMOR SUMMARY				
TOTAL ANIMALS WITH PRIMARY TUMORS*	3	3	13	5
TOTAL PRIMARY TUMORS	3	3	18	6
TOTAL ANIMALS WITH BENIGN TUMORS	1	2	13	4
TOTAL BENIGN TUMORS	1	2	16	4
TOTAL ANIMALS WITH MALIGNANT TUMORS	2	1	2	2
TOTAL MALIGNANT TUMORS	2	1	2	2
TOTAL ANIMALS WITH SECONDARY TUMORS*				
TOTAL SECONDARY TUMORS				
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT				
TOTAL UNCERTAIN TUMORS				
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC				
TOTAL UNCERTAIN TUMORS				
* PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS				
* SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN				

TABLE A2.

**SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS
TREATED WITH EMETINE**

	UNTREATED CONTROL	VEHICLE CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	10	10	35	35
ANIMALS NECROPSIED	10	10	35	35
ANIMALS EXAMINED HISTOPATHOLOGICALLY	10	10	35	35
INTEGUMENTARY SYSTEM				
*SUBCUT TISSUE	(10)	(10)	(35)	(35)
FIBROSARCOMA			1 (3%)	
LIPOMA			1 (3%)	
LIPOSARCOMA			1 (3%)	
RESPIRATORY SYSTEM				
*LUNG	(10)	(9)	(34)	(35)
ADENOCARCINOMA, NOS, METASTATIC	1 (10%)			
SARCOMA, NOS, METASTATIC				1 (3%)
HEMATOPOIETIC SYSTEM				
NONE				
CIRCULATORY SYSTEM				
NONE				
DIGESTIVE SYSTEM				
NONE				
URINARY SYSTEM				
NONE				
ENDOCRINE SYSTEM				
*PITUITARY	(10)	(10)	(35)	(33)
CHROMOPHOBE ADENOMA	3 (30%)	3 (30%)	11 (31%)	8 (24%)
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)

	UNTREATED CONTROL	VEHICLE CONTROL	LOW DOSE	HIGH DOSE
CHROMOPHOBE CARCINOMA	1 (10%)	1 (10%)	1 (3%)	1 (3%)
ACIDOPHIL ADENOMA			1 (3%)	
*ADRENAL	(10)	(10)	(35)	(35)
CORTICAL ADENOMA	1 (10%)	3 (30%)	9 (26%)	2 (6%)
PHEOCHROMOCYTOMA			1 (3%)	
#THYROID	(10)	(7)	(28)	(24)
C-CELL ADENOMA			1 (4%)	1 (4%)
#PANCREATIC ISLETS	(10)	(10)	(35)	(34)
ISLET-CELL ADENOMA			1 (3%)	
REPRODUCTIVE SYSTEM				
*MAMMARY GLAND	(10)	(10)	(35)	(35)
ADENOMA, NOS			1 (3%)	
ADENOCARCINOMA, NOS	1 (10%)		1 (3%)	2 (6%)
PAPILLARY ADENOMA			1 (3%)	
FIBROMA	1 (10%)			1 (3%)
FIBROADENOMA	1 (10%)	2 (20%)	14 (40%)	10 (29%)
#UTERUS	(10)	(10)	(35)	(35)
SQUAMOUS CELL CARCINOMA			1 (3%)	
SARCOMA, NOS				1 (3%)
LEIOMYOMA				1 (3%)
LEIOMYOSARCOMA			1 (3%)	1 (3%)
ENDOMETRIAL STROMAL POLYP	1 (10%)		3 (9%)	1 (3%)
NERVOUS SYSTEM				
NONE				
SPECIAL SENSE ORGANS				
NONE				
MUSCULOSKELETAL SYSTEM				
NONE				
BODY CAVITIES				
*MESENTERY	(10)	(10)	(35)	(35)
LIPOMA				2 (6%)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY

* NUMBER OF ANIMALS REPORTED

TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)

	UNTREATED CONTROL	VEHICLE CONTROL	LDW DDSE	HIGH DDSE
ALL OTHER SYSTEMS				
NONE				
ANIMAL DISPOSITION SUMMARY				
ANIMALS INITIALLY IN STUDY	10	10	35	35
NATURAL DEATH ^a	1		1	1
MORIBUND SACRIFICE	2		5	10
SCHEDULED SACRIFICE				
ACCIDENTALLY KILLED				
TERMINAL SACRIFICE	7	10	29	24
ANIMAL MISSING				
^a INCLUDES AUTOLYZED ANIMALS				
TUMOR SUMMARY				
TOTAL ANIMALS WITH PRIMARY TUMORS*	7	6	26	22
TOTAL PRIMARY TUMORS	9	9	50	31
TOTAL ANIMALS WITH BENIGN TUMORS	5	6	22	20
TOTAL BENIGN TUMORS	7	8	44	26
TOTAL ANIMALS WITH MALIGNANT TUMORS	2	1	5	5
TOTAL MALIGNANT TUMORS	2	1	6	5
TOTAL ANIMALS WITH SECONDARY TUMORS [#]	1			1
TOTAL SECONDARY TUMORS	1			1
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT				
TOTAL UNCERTAIN TUMORS				
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC				
TOTAL UNCERTAIN TUMORS				
* PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS				
[#] SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN				

APPENDIX B

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN
MICE TREATED WITH EMETINE

TABLE B1.

**SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE
TREATED WITH EMETINE (CONTROL GROUPS)**

	MID & HIGH DOSE UNTREATED CONTROL	LOW DOSE, UNTREATED CONTROL	MID & HIGH DOSE VEHICLE CONTROL	LOW DOSE VEHICLE CONTROL
ANIMALS INITIALLY IN STUDY	15	10	15	10
ANIMALS MISSING	1			
ANIMALS NECROPSIED	14	10	14	10
ANIMALS EXAMINED HISTOPATHOLOGICALLY	14	10	14	10
INTEGUMENTARY SYSTEM				
NONE				
RESPIRATORY SYSTEM				
*LUNG	(14)	(9)	(14)	(10)
ALVEOLAR/BRONCHIOLAR ADENOMA			1 (7%)	
HEMATOPOIETIC SYSTEM				
*MULTIPLE ORGANS	(14)	(10)	(14)	(10)
MONOCYTIC LEUKEMIA				1 (10%)
CIRCULATORY SYSTEM				
NONE				
DIGESTIVE SYSTEM				
*LIVER	(14)	(10)	(14)	(10)
HEPATOCELLULAR ADENOMA	2 (14%)		1 (7%)	
HEPATOCELLULAR CARCINOMA	1 (7%)			
URINARY SYSTEM				
NONE				
ENDOCRINE SYSTEM				
NONE				
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE B1. MALE MICE: NEOPLASMS (CONTINUED)

	MIO & HIGH DOSE UNTREATED CONTROL	LOW DOSE UNTREATED CONTROL	MIO & HIGH DOSE VEHICLE CONTROL	LOW DOSE VEHICLE CONTROL
REPRODUCTIVE SYSTEM				
NONE				
NERVOUS SYSTEM				
NONE				
SPECIAL SENSE ORGANS				
NONE				
MUSCULOSKELETAL SYSTEM				
NONE				
BODY CAVITIES				
NONE				
ALL OTHER SYSTEMS				
NONE				
ANIMAL DISPOSITION SUMMARY				
ANIMALS INITIALLY IN STUDY	15	10	15	10
NATURAL DEATH ^a	2	1	2	1
MORIBUND SACRIFICE	1			1
SCHEDULED SACRIFICE				
ACCIDENTALLY KILLED				
TERMINAL SACRIFICE	11	9	13	8
ANIMAL MISSING	1			
^a INCLUDES AUTOLYZED ANIMALS				
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE B1. MALE MICE: NEOPLASMS (CONTINUED)

	MID & HIGH DOSE UNTREATED CONTROL	LOW DOSE UNTREATED CONTROL	MID & HIGH DOSE VEHICLE CONTROL	LDW DOSE VEHICLE CONTROL
TUMOR SUMMARY				
TOTAL ANIMALS WITH PRIMARY TUMORS*	3		2	1
TOTAL PRIMARY TUMORS	3		2	1
TOTAL ANIMALS WITH BENIGN TUMORS	2		2	
TOTAL BENIGN TUMORS	2		2	
TOTAL ANIMALS WITH MALIGNANT TUMORS	1			1
TOTAL MALIGNANT TUMORS	1			1
TOTAL ANIMALS WITH SECONDARY TUMORS#				
TOTAL SECONDARY TUMORS				
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT				
TOTAL UNCERTAIN TUMORS				
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC				
TOTAL UNCERTAIN TUMORS				
* PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS				
# SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN				

TABLE B2.

**SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE
TREATED WITH EMETINE (TREATED GROUPS)**

	LOW DOSE	MID DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	35	35	35
ANIMALS NECROPSIED	35	30	30
ANIMALS EXAMINED HISTOPATHOLOGICALLY	35	29	30

INTEGUMENTARY SYSTEM			
NONE			

RESPIRATORY SYSTEM			
#LUNG	(35)	(28)	(29)
ALVEOLAR/BRONCHIOLAR ADENOMA	2 (6%)		
ALVEOLAR/BRONCHIOLAR CARCINOMA	1 (3%)		

HEMATOPOIETIC SYSTEM			
NONE			

CIRCULATORY SYSTEM			
NONE			

DIGESTIVE SYSTEM			
#LIVER	(35)	(27)	(30)
HEPATOCELLULAR CARCINOMA	3 (9%)		

URINARY SYSTEM			
NONE			

ENDOCRINE SYSTEM			
#THYROID	(25)	(19)	(16)
PAPILLARY CYSTADENOMA, NOS	1 (4%)		

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

TABLE B2. MALE MICE: NEOPLASMS (CONTINUED)

	LOW DOSE	MID DOSE	HIGH DO
REPRODUCTIVE SYSTEM			
NONE			
NERVOUS SYSTEM			
NONE			
SPECIAL SENSE ORGANS			
NONE			
MUSCULOSKELETAL SYSTEM			
NONE			
BODY CAVITIES			
NONE			
ALL OTHER SYSTEMS			
NONE			
ANIMAL DISPOSITION SUMMARY			
ANIMALS INITIALLY IN STUDY	35	35	35
NATURAL DEATH ^a	7	24	18
MORIBUND SACRIFICE	13	10	17
SCHEDULED SACRIFICE			
ACCIDENTALLY KILLED	1	1	
TERMINAL SACRIFICE	14		
ANIMAL MISSING			
^a INCLUDES AUTOLYZED ANIMALS			
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

TABLE B2. MALE MICE: NEOPLASMS (CONTINUED)

	LOW DOSE	MID DOSE	HIGH DOSE
TUMOR SUMMARY			
TOTAL ANIMALS WITH PRIMARY TUMORS*	7		
TOTAL PRIMARY TUMORS	7		
TOTAL ANIMALS WITH BENIGN TUMORS	3		
TOTAL BENIGN TUMORS	3		
TOTAL ANIMALS WITH MALIGNANT TUMORS	4		
TOTAL MALIGNANT TUMORS	4		
TOTAL ANIMALS WITH SECONDARY TUMORS#			
TOTAL SECONDARY TUMORS			
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT			
TOTAL UNCERTAIN TUMORS			
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC			
TOTAL UNCERTAIN TUMORS			
* PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS			
# SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN			

TABLE B3.

**SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE
TREATED WITH EMETINE (CONTROL GROUPS)**

	MIO & HIGH DOSE UNTREATED CONTROL	LOW DOSE UNTREATED CONTROL	MIO & HIGH DOSE VEHICLE CONTROL	LOW DOSE VEHICLE CONTROL
ANIMALS INITIALLY IN STUDY	15	10	15	10
ANIMALS NECROPSIED	15	10	15	10
ANIMALS EXAMINED HISTOPATHOLOGICALLY	15	10	15	10

INTEGUMENTARY SYSTEM

NONE

RESPIRATORY SYSTEM

NONE

HEMATOPOIETIC SYSTEM

*MULTIPLE ORGANS LYMPHOCYTIC LEUKEMIA	(15)	(10) 1 (10%)	(15)	(10)
*MESENTERIC L. NODE MALIG. LYMPHOMA, UNDIFFER-TYPE	(6)	(8) 1 (13%)	(6)	(8)

CIRCULATORY SYSTEM

NONE

DIGESTIVE SYSTEM

NONE

URINARY SYSTEM

NONE

ENDOCRINE SYSTEM

NONE

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY

* NUMBER OF ANIMALS NECROPSIED

TABLE B3. FEMALE MICE: NEOPLASMS (CONTINUED)

	MID & HIGH DOSE UNTREATED CONTROL	LOW DOSE UNTREATED CONTROL	MID & HIGH DOSE VEHICLE CONTROL	LOW DOSE VEHICLE CONTROL
REPRODUCTIVE SYSTEM				
#UTERUS	(15)	(9)	(15)	(10)
ENDOMETRIAL STROMAL POLYP	1 (7%)			
NERVOUS SYSTEM				
NONE				
SPECIAL SENSE ORGANS				
NONE				
MUSCULOSKELETAL SYSTEM				
NONE				
BODY CAVITIES				
NONE				
ALL OTHER SYSTEMS				
NONE				
ANIMAL DISPOSITION SUMMARY				
ANIMALS INITIALLY IN STUDY	15	10	15	10
NATURAL DEATH	3			2
MORIBUND SACRIFICE		1		2
SCHEDULED SACRIFICE				
ACCIDENTALLY KILLED				
TERMINAL SACRIFICE	12	9	15	6
ANIMAL MISSING				
@ INCLUDES AUTOLYZED ANIMALS				
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE B3. FEMALE MICE: NEOPLASMS (CONTINUED)

	MID & HIGH DOSE UNTREATED CONTROL	LOW DOSE UNTREATED CONTROL	MID & HIGH DOSE VEHICLE CONTROL	LDW DOSE VEHICLE CONTROL
TUMOR SUMMARY				
TOTAL ANIMALS WITH PRIMARY TUMORS*	1	2		
TOTAL PRIMARY TUMORS	1	2		
TOTAL ANIMALS WITH BENIGN TUMORS	1			
TOTAL BENIGN TUMORS	1			
TOTAL ANIMALS WITH MALIGNANT TUMORS		2		
TOTAL MALIGNANT TUMORS		2		
TOTAL ANIMALS WITH SECONDARY TUMORS#				
TOTAL SECONDARY TUMORS				
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT				
TOTAL UNCERTAIN TUMORS				
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC				
TOTAL UNCERTAIN TUMORS				
* PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS				
# SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN				

TABLE B4.

**SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE
TREATED WITH EMETINE (TREATED GROUPS)**

	LOW DOSE	MID DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	35	35	35
ANIMALS MISSING		1	
ANIMALS NECROPSIED	34	26	27
ANIMALS EXAMINED HISTOPATHOLOGICALLY	34	26	27
INTEGUMENTARY SYSTEM			
NONE			
RESPIRATORY SYSTEM			
*LUNG	(33)	(26)	(27)
ALVEOLAR/BRONCHIOLAR ADENOMA			1 (4%)
HEMATOPOIETIC SYSTEM			
NONE			
CIRCULATORY SYSTEM			
NONE			
DIGESTIVE SYSTEM			
NONE			
URINARY SYSTEM			
NONE			
ENDOCRINE SYSTEM			
*THYROID	(31)	(12)	(16)
ADENOMA, NOS	1 (3%)		
REPRODUCTIVE SYSTEM			
NONE			
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

TABLE B4. FEMALE MICE: NEOPLASMS (CONTINUED)

	LOW DOSE	MID DOSE	HIGH DOSE
NERVOUS SYSTEM			
NONE			
SPECIAL SENSE ORGANS			
NONE			
MUSCULOSKELETAL SYSTEM			
NONE			
BODY CAVITIES			
*MESENTERY	(34)	(26)	(27)
LIPOMA	1 (3%)		
ALL OTHER SYSTEMS			
NONE			
ANIMAL DISPOSITION SUMMARY			
ANIMALS INITIALLY IN STUDY	35	35	35
NATURAL DEATH@	5	19	23
MORIBUND SACRIFICE	19	15	12
SCHEDULED SACRIFICE			
ACCIDENTALLY KILLED			
TERMINAL SACRIFICE	11		
ANIMAL MISSING		1	
@ INCLUDES AUTOLYZED ANIMALS			
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

TABLE B4. FEMALE MICE: NEOPLASMS (CONTINUED)

	LOW DOSE	MID DOSE	HIGH DOSE
TUMOR SUMMARY			
TOTAL ANIMALS WITH PRIMARY TUMORS*	2		1
TOTAL PRIMARY TUMORS	2		1
TOTAL ANIMALS WITH BENIGN TUMORS	2		1
TOTAL BENIGN TUMORS	2		1
TOTAL ANIMALS WITH MALIGNANT TUMORS			
TOTAL MALIGNANT TUMORS			
TOTAL ANIMALS WITH SECONDARY TUMORS#			
TOTAL SECONDARY TUMORS			
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT			
TOTAL UNCERTAIN TUMORS			
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC			
TOTAL UNCERTAIN TUMORS			
* PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS			
# SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN			

APPENDIX C

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS
IN RATS TREATED WITH EMETINE

TABLE C1.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS TREATED WITH EMETINE

	UNTREATED CONTROL	VEHICLE CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	10	10	35	35
ANIMALS NECROPSIED	10	10	35	27
ANIMALS EXAMINED HISTOPATHOLOGICALLY	10	10	35	27
INTEGUMENTARY SYSTEM				
*SKIN	(10)	(10)	(35)	(27)
EPIDERMAL INCLUSION CYST			2 (6%)	
RESPIRATORY SYSTEM				
*TRACHEA	(10)	(10)	(34)	(26)
INFLAMMATION, NOS	3 (30%)	5 (50%)	6 (18%)	
LYMPHOCYTIC INFILTRATE	1 (10%)			
INFLAMMATION, SUPPURATIVE			1 (3%)	1 (4%)
INFLAMMATION, ACUTE/CHRONIC			3 (9%)	
INFLAMMATION, CHRONIC				1 (4%)
*LUNG/BRONCHUS	(10)	(10)	(35)	(27)
BRONCHIECTASIS	1 (10%)			
INFLAMMATION, NOS			2 (6%)	
INFLAMMATION, ACUTE/CHRONIC			1 (3%)	
INFLAMMATION, CHRONIC		1 (10%)	1 (3%)	
*LUNG/BRONCHIOLE	(10)	(10)	(35)	(27)
INFLAMMATION, SUPPURATIVE	1 (10%)			
PERIVASCULAR CUFFING			1 (3%)	
HYPERPLASIA, LYMPHOID			1 (3%)	
*LUNG	(10)	(10)	(35)	(27)
EMPHYSEMA, NOS				1 (4%)
ABSCCESS, NOS	1 (10%)			
PNEUMONIA INTERSTITIAL CHRONIC		1 (10%)		1 (4%)
HEMATOPOIETIC SYSTEM				
*BONE MARROW	(10)	(10)	(35)	(27)
ATROPHY, NOS			12 (34%)	5 (19%)
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

	UNTREATED CONTROL	VEHICLE CONTROL	LOW DOSE	HIGH DOSE
CIRCULATORY SYSTEM				
#HEART CALCIFICATION, NOS	(10)	(10)	(35)	(27) 2 (7%)
#MYOCARDIUM INFLAMMATION, NOS INFLAMMATION, INTERSTITIAL	(10)	(10)	(35)	(27) 2 (7%) 1 (4%)
DIGESTIVE SYSTEM				
#LIVER INFLAMMATION, SUPPURATIVE NECROSIS, COAGULATIVE	(10)	(10)	(35) 1 (3%)	(27) 1 (4%)
#PANCREAS INFLAMMATION, CHRONIC	(10)	(9)	(34) 1 (3%)	(26)
URINARY SYSTEM				
#KIDNEY PYELONEPHRITIS, NOS ABSCESS, NOS INFLAMMATION, CHRONIC NEPHROSIS, NOS	(10) 1 (10%) 4 (40%)	(10) 1 (10%)	(35) 10 (29%)	(27) 1 (4%) 2 (7%) 4 (15%)
#KIDNEY/GLOMERULUS INFLAMMATION, NOS FIBROSIS	(10)	(10)	(35) 1 (3%) 5 (14%)	(27)
#URINARY BLADDER HYPERPLASIA, EPITHELIAL	(9)	(9)	(26)	(24) 3 (13%)
ENDOCRINE SYSTEM				
#ADRENAL ABSCESS, NOS	(9) 1 (11%)	(10)	(35)	(27)
REPRODUCTIVE SYSTEM				
#PROSTATE INFLAMMATION, SUPPURATIVE	(9) 1 (11%)	(10)	(33)	(26) 3 (12%)
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

	UNTREATED CONTROL	VEHICLE CONTROL	LOW DOSE	HIGH DOSE
INFLAMMATION, ACUTE SUPPURATIVE				1 (4%)
INFLAMMATION, CHRONIC				1 (4%)
INFLAMMATION, CHRONIC SUPPURATIVE	1 (11%)			2 (8%)
*SEMINAL VESICLE INFLAMMATION, ACUTE/CHRONIC	(10)	(10)	(35)	(27) 1 (4%)
NERVOUS SYSTEM				
*CEREBELLUM GLIOSIS	(10)	(10)	(35) 1 (3%)	(25)
SPECIAL SENSE ORGANS				
NONE				
MUSCULOSKELETAL SYSTEM				
*JOINT INFLAMMATION, SUPPURATIVE	(10) 1 (10%)	(10)	(35)	(27)
*SKELETAL MUSCLE FIBROSIS	(10) 1 (10%)	(10)	(35)	(27)
ATROPHY, FOCAL	1 (10%)			
BODY CAVITIES				
*PERITONEUM INFLAMMATION, CHRONIC	(10)	(10)	(35)	(27) 1 (4%)
ALL OTHER SYSTEMS				
NONE				
SPECIAL MORPHOLOGY SUMMARY				
NO LESION REPORTED	1	2	4	8
AUTOLYSIS/NO NECROPSY				8
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE C2.

**SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS
TREATED WITH EMETINE**

	UNTREATED CONTROL	VEHICLE CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	10	10	35	35
ANIMALS NECROPSIED	10	10	35	35
ANIMALS EXAMINED HISTOPATHOLOGICALLY	10	10	35	35
INTEGUMENTARY SYSTEM				
*SUBCUT TISSUE EDEMA, NOS	(10)	(10)	(35)	(35) 1 (3%)
RESPIRATORY SYSTEM				
#TRACHEA	(10)	(10)	(34)	(32)
INFLAMMATION, NOS	1 (10%)	3 (30%)	11 (32%)	
INFLAMMATION, SUPPURATIVE			1 (3%)	
INFLAMMATION, ACUTE/CHRONIC			5 (15%)	5 (16%)
HYPERPLASIA, PLASMA CELL			1 (3%)	
#LUNG/BRONCHUS	(10)	(9)	(34)	(35)
BRONCHIECTASIS			1 (3%)	
INFLAMMATION, NOS			1 (3%)	
INFLAMMATION, CHRONIC SUPPURATIVE			1 (3%)	
#LUNG	(10)	(9)	(34)	(35)
EMPHYSEMA, NOS				1 (3%)
BRONCHOPNEUMONIA SUPPURATIVE				1 (3%)
BRONCHOPNEUMONIA CHRONIC SUPPURA				1 (3%)
HEMATOPOIETIC SYSTEM				
*BONE MARROW	(10)	(10)	(35)	(35)
ATROPHY, NOS			1 (3%)	8 (23%)
CIRCULATORY SYSTEM				
NONE				
DIGESTIVE SYSTEM				
NONE				
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

	UNTREATED CONTROL	VEHICLE CONTROL	LOW DOSE	HIGH DOSE
URINARY SYSTEM				
*KIDNEY INFLAMMATION, INTERSTITIAL INFLAMMATION, CHRONIC	(10)	(10)	(35) 1 (3%) 4 (11%)	(35) 1 (3%)
*KIDNEY/GLOMERULUS FIBROSIS	(10)	(10)	(35) 1 (3%)	(35)
*KIDNEY/TUBULE MINERALIZATION	(10)	(10)	(35)	(35) 1 (3%)
ENDOCRINE SYSTEM				
NONE				
REPRODUCTIVE SYSTEM				
*MAMMARY GLAND HYPERPLASIA, CYSTIC	(10)	(10)	(35)	(35) 1 (3%)
*UTERUS PYOMETRA	(10) 1 (10%)	(10) 1 (10%)	(35) 2 (6%)	(35)
*UTERUS/ENDOMETRIUM INFLAMMATION, SUPPURATIVE	(10) 1 (10%)	(10)	(35)	(35) 2 (6%)
*OVARY CYST, NOS ABSCESS, NOS	(10)	(3)	(32) 1 (3%)	(27) 1 (4%)
NERVOUS SYSTEM				
NONE				
SPECIAL SENSE ORGANS				
*EAR/CARTILAGE HYPERPLASIA, NOS METAPLASIA, OSSEOUS	(10)	(10)	(35)	(35) 1 (3%) 1 (3%)
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)

	UNTREATED CONTROL	VEHICLE CONTROL	LOW DOSE	HIGH DOSE
MUSCULOSKELETAL SYSTEM				
*SKELETAL MUSCLE MINERALIZATION	(10)	(10)	(35)	(35) 1 (3%)
BODY CAVITIES				
*PERITONEUM INFLAMMATION, CHRONIC SUPPURATIVE	(10)	(10)	(35)	(35) 1 (3%)
ALL OTHER SYSTEMS				
NONE				
SPECIAL MORPHOLOGY SUMMARY				
NO LESION REPORTED	1	2	3	2
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

APPENDIX D

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS
IN MICE TREATED WITH EMETINE

TABLE D1.

**SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE
TREATED WITH EMETINE (CONTROL GROUPS)**

	MID & HIGH DOSE UNTREATED CONTROL	LOW DOSE UNTREATED CONTROL	MID & HIGH DOSE VEHICLE CONTROL	LOW DOSE VEHICLE CONTROL
ANIMALS INITIALLY IN STUDY	15	10	15	10
ANIMALS MISSING	1			
ANIMALS NECROPSIED	14	10	14	10
ANIMALS EXAMINED HISTOPATHOLOGICALLY	14	10	14	10
INTEGUMENTARY SYSTEM				
*SKIN	(14)	(10)	(14)	(10)
INFLAMMATION, NOS	2 (14%)			
*SUBCUT TISSUE	(14)	(10)	(14)	(10)
LIPOGRANULOMA				1 (10%)
RESPIRATORY SYSTEM				
*TRACHEA	(13)	(8)	(13)	(9)
INFLAMMATION, SUPPURATIVE				1 (11%)
*LUNG	(14)	(9)	(14)	(10)
EDEMA, NOS	1 (7%)			
INFLAMMATION, INTERSTITIAL	1 (7%)			1 (10%)
BRONCHOPNEUMONIA SUPPURATIVE	1 (7%)			
BRONCHOPNEUMONIA CHRONIC SUPPURA				1 (10%)
HEMATOPOIETIC SYSTEM				
*SPLEEN	(14)	(9)	(14)	(10)
HEMATOPOIESIS			2 (14%)	1 (10%)
*MESENTERIC L. NODE	(7)	(4)	(11)	(9)
INFLAMMATION, SUPPURATIVE			1 (9%)	
INFLAMMATION, NECROTIZING			1 (9%)	
HYPERPLASIA, HEMATOPOIETIC	1 (14%)			
HYPERPLASIA, LYMPHOID			2 (18%)	3 (33%)
*THYMUS	(8)	(1)	(10)	
ATROPHY, NOS	1 (13%)			
CIRCULATORY SYSTEM				
*HEART	(14)	(10)	(14)	(10)
PERIARTERITIS			1 (7%)	
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

	MID & HIGH DOSE UNTREATED CONTROL	LDW DDSE UNTREATED CONTROL	MID & HIGH DDSE VEHICLE CONTROL	LDW DDSE VEHICLE CONTROL
DIGESTIVE SYSTEM				
#LIVER	(14)	(10)	(14)	(10)
INFLAMMATION, CHRONIC			1 (7%)	
HYPERPLASTIC NODULE	1 (7%)	1 (10%)	3 (21%)	
URINARY SYSTEM				
NONE				
ENDOCRINE SYSTEM				
#THYROID	(13)	(4)	(10)	(9)
PERIARTERITIS	1 (8%)			
REPRODUCTIVE SYSTEM				
*SEMINAL VESICLE	(14)	(10)	(14)	(10)
HYPERPLASIA, CYSTIC	1 (7%)			
NERVOUS SYSTEM				
NONE				
SPECIAL SENSE ORGANS				
NONE				
MUSCULOSKELETAL SYSTEM				
NONE				
BODY CAVITIES				
NONE				
ALL OTHER SYSTEMS				
*MULTIPLE ORGANS	(14)	(10)	(14)	(10)
CYTOMEGALY				1 (10%)
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

	MID & HIGH DOSE UNTREATED CONTROL	LOW DOSE UNTREATED CONTROL	MID & HIGH DOSE VEHICLE CONTROL	LOW DOSE VEHICLE CONTROL
SPECIAL MORPHOLOGY SUMMARY				
NO LESION REPORTED	7	9	7	4
ANIMAL MISSING/NO NECROPSY	1			
AUTOLYSIS/NO NECROPSY			1	
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY * NUMBER OF ANIMALS NECROPSIED				

TABLE D2.

**SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE
TREATED WITH EMETINE (TREATED GROUPS)**

	LOW DOSE	MID DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	35	35	35
ANIMALS NECROPSIED	35	30	30
ANIMALS EXAMINED HISTOPATHOLOGICALLY	35	29	30
INTEGUMENTARY SYSTEM			
NONE			
RESPIRATORY SYSTEM			
#TRACHEA	(35)	(28)	(28)
INFLAMMATION, SUPPURATIVE	11 (31%)		
INFLAMMATION, ACUTE/CHRONIC	1 (3%)		
#LUNG/BRONCHUS	(35)	(28)	(29)
BRONCHIECTASIS	12 (34%)		
INFLAMMATION, NOS	2 (6%)		
INFLAMMATION, SUPPURATIVE	10 (29%)		
#LUNG/BRONCHIOLE	(35)	(28)	(29)
INFLAMMATION, FOCAL	1 (3%)		
INFLAMMATION, SUPPURATIVE	2 (6%)		
#LUNG	(35)	(28)	(29)
EDEMA, NOS	1 (3%)		
HEMORRHAGE	1 (3%)		
BRONCHOPNEUMONIA, NOS	10 (29%)		
INFLAMMATION, INTERSTITIAL	1 (3%)		
INFLAMMATION, SUPPURATIVE	1 (3%)		
BRONCHOPNEUMONIA SUPPURATIVE	5 (14%)		
BRONCHOPNEUMONIA, ACUTE	1 (3%)		
INFLAMMATION, ACUTE HEMORRHAGIC	1 (3%)		
INFLAMMATION, ACUTE/CHRONIC	1 (3%)		
BRONCHOPNEUMONIA CHRONIC SUPPURA	3 (9%)		
HEMATOPOIETIC SYSTEM			
#SPLEEN	(34)	(22)	(25)
HEMATOPOIESIS	5 (15%)		
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

TABLE D2. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

	LOW DOSE	MID DOSE	HIGH DOSE
#MANDIBULAR L. NODE ATROPHY, NOS	(32) 1 (3%)	(22)	(19)
#MEDIASTINAL L.NODE PLASMACYTOSIS	(32) 1 (3%)	(22)	(19)
#MESENTERIC L. NODE INFLAMMATION, NECROTIZING INFLAMMATION, CHRONIC	(32) 1 (3%)	(22)	(19) 1 (5%)
#THYMUS ATROPHY, NOS	(6) 6 (100%)	(1)	
CIRCULATORY SYSTEM			
#HEART DEGENERATION, NOS NECROSIS, NOS	(35) 2 (6%) 2 (6%)	(27)	(29)
#HEART/ATRIUM THROMBOSIS, NOS	(35) 1 (3%)	(27)	(29)
#MYOCARDIUM INFLAMMATION, NOS INFLAMMATION, INTERSTITIAL INFLAMMATION, SUPPURATIVE	(35) 1 (3%) 2 (6%) 1 (3%)	(27)	(29)
DIGESTIVE SYSTEM			
#LIVER INFLAMMATION, SUPPURATIVE NECROSIS, FOCAL NECROSIS, COAGULATIVE BASOPHILIC CYTO CHANGE FOCAL CELLULAR CHANGE	(35) 1 (3%) 2 (6%) 1 (3%)	(27) 1 (4%) 3 (11%)	(30) 1 (3%)
#PANCREAS INFLAMMATION, CHRONIC	(33) 1 (3%)	(26) 1 (4%)	(29)
#PANCREATIC ACINUS ATROPHY, NOS	(33)	(26) 1 (4%)	(29)
#ESOPHAGUS ULCER, NOS	(34) 1 (3%)	(24)	(24) 1 (4%)

NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY
* NUMBER OF ANIMALS NECROPSIED

TABLE D2. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

	LOW DOSE	MID DOSE	HIGH DOSE
INFLAMMATION, SUPPURATIVE ULCER, CHRONIC	1 (3%)	2 (8%)	1 (4%)
#SMALL INTESTINE HEMORRHAGE	(26)	(27)	(15) 1 (7%)
#DUODENUM HEMORRHAGE	(26)	(27)	(15) 1 (7%)
#ILEUM INFLAMMATION, HEMORRHAGIC	(26)	(27)	(15) 1 (7%)
URINARY SYSTEM			
NONE			
ENDOCRINE SYSTEM			
NONE			
REPRODUCTIVE SYSTEM			
#PROSTATE ULCER, NOS	(21) 1 (5%)	(22)	(15)
INFLAMMATION, SUPPURATIVE	1 (5%)		
*SEMINAL VESICLE INFLAMMATION, SUPPURATIVE	(35) 1 (3%)	(30)	(30)
INFLAMMATION, CHRONIC	1 (3%)		
NERVOUS SYSTEM			
#BRAIN/MENINGES INFLAMMATION, SUPPURATIVE	(35) 1 (3%)	(28)	(29)
SPECIAL SENSE ORGANS			
NONE			
MUSCULOSKELETAL SYSTEM			
NONE			
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

TABLE D2. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

	LOW DOSE	MID DOSE	HIGH DOSE
BODY CAVITIES			
*PERITONEUM	(35)	(30)	(30)
INFLAMMATION, SUPPURATIVE	2 (6%)		
INFLAMMATION, CHRONIC	2 (6%)		
INFLAMMATION, CHRONIC NECROTIZIN			1 (3%)
FIBROSIS	2 (6%)		
HEMOSIDEROSIS	1 (3%)		
*VISCERAL PERITONEUM	(35)	(30)	(30)
INFLAMMATION, HEMORRHAGIC		1 (3%)	2 (7%)
INFLAMMATION, CHRONIC		16 (53%)	12 (40%)
INFLAMMATION, CHRONIC NECROTIZIN			2 (7%)
*PLEURA	(35)	(30)	(30)
INFLAMMATION, SUPPURATIVE		1 (3%)	
INFLAMMATION, CHRONIC NECROTIZIN		1 (3%)	
ALL OTHER SYSTEMS			
NONE			
SPECIAL MORPHOLOGY SUMMARY			
NO LESION REPORTED	5	12	12
NECROPSY PERF/NO HISTO PERFORMED		1	
NO NECROPSY PERFORMED		1	1
AUTOLYSIS/NO NECROPSY		4	4
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

TABLE D3.

**SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE
TREATED WITH EMETINE (CONTROL GROUPS)**

	MID & HIGH DOSE UNTREATED CONTROL	LOW DOSE UNTREATED CONTROL	MID & HIGH DOSE VEHICLE CONTROL	LOW DOSE VEHICLE CONTROL
ANIMALS INITIALLY IN STUDY	15	10	15	10
ANIMALS NECROPSIED	15	10	15	10
ANIMALS EXAMINED HISTOPATHOLOGICALLY	15	10	15	10
INTEGUMENTARY SYSTEM				
*SKIN	(15)	(10)	(15)	(10)
INFLAMMATION, NOS	1 (7%)			
INFLAMMATION, SUPPURATIVE	1 (7%)			
RESPIRATORY SYSTEM				
*TRACHEA	(14)	(7)	(14)	(9)
INFLAMMATION, SUPPURATIVE				2 (22%)
*LUNG/BRONCHUS	(15)	(10)	(14)	(9)
INFLAMMATION, CHRONIC SUPPURATIVE				1 (11%)
*LUNG	(15)	(10)	(14)	(9)
CONGESTION, NOS	1 (7%)			
EDEMA, NOS	2 (13%)			
HEMORRHAGE	1 (7%)			
BRONCHOPNEUMONIA CHRONIC SUPPURA				4 (44%)
HEMATOPOIETIC SYSTEM				
*SPLEEN	(13)	(10)	(15)	(10)
HEMATOPOIESIS			3 (20%)	4 (40%)
CIRCULATORY SYSTEM				
*MYOCARDIUM	(15)	(10)	(15)	(9)
INFLAMMATION, ACUTE	1 (7%)			
DIGESTIVE SYSTEM				
*LIVER	(14)	(10)	(15)	(10)
INFLAMMATION, SUPPURATIVE				1 (10%)
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE D3. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

	MID & HIGH DOSE UNTREATED CONTROL	LOW DOSE UNTREATED CONTROL	MID & HIGH DOSE VEHICLE CONTROL	LOW DOSE VEHICLE CONTROL
*STOMACH INFLAMMATION, SUPPURATIVE HYPERPLASIA, NOS	(14) 1 (7%) 1 (7%)	(8)	(15)	(10)
URINARY SYSTEM				
NONE				
ENDOCRINE SYSTEM				
NONE				
REPRODUCTIVE SYSTEM				
*MAMMARY GLAND HYPERPLASIA, CYSTIC	(15) 1 (7%)	(10)	(15)	(10)
*UTERUS INFLAMMATION, SUPPURATIVE PYOMETRA	(15) 1 (7%) 3 (20%)	(9)	(15)	(10)
*UTERUS/ENDOMETRIUM HYPERPLASIA, CYSTIC	(15) 10 (67%)	(9) 8 (89%)	(15) 14 (93%)	(10) 8 (80%)
NERVOUS SYSTEM				
NONE				
SPECIAL SENSE ORGANS				
*EAR THROMBOSIS, NOS HEMORRHAGE	(15) 1 (7%) 1 (7%)	(10)	(15)	(10)
MUSCULOSKELETAL SYSTEM				
NONE				
BODY CAVITIES				
*PERITONEUM INFLAMMATION, SUPPURATIVE	(15) 1 (7%)	(10)	(15)	(10)
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE D3. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

	MID & HIGH DOSE UNTREATED CONTROL	LOW DOSE UNTREATED CONTROL	MID & HIGH DOSE VEHICLE CONTROL	LOW DOSE VEHICLE CONTROL
*PLEURA INFLAMMATION, SUPPURATIVE	(15) 1 (7%)	(10)	(15)	(10)
*EPICARDIUM INFLAMMATION, SUPPURATIVE	(15) 1 (7%)	(10)	(15)	(10)
ALL OTHER SYSTEMS				
NONE				
SPECIAL MORPHOLOGY SUMMARY				
NO LESION REPORTED	1	2	1	
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY				
* NUMBER OF ANIMALS NECROPSIED				

TABLE D4.

**SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE
TREATED WITH EMETINE (TREATED GROUPS)**

	LOW DOSE	MID DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	35	35	35
ANIMALS MISSING		1	
ANIMALS NECROPSIED	34	26	27
ANIMALS EXAMINED HISTOPATHOLOGICALLY	34	26	27
INTEGUMENTARY SYSTEM			
NONE			
RESPIRATORY SYSTEM			
*TRACHEA	(34)	(19)	(27)
INFLAMMATION, SUPPURATIVE	1 (3%)		
*LUNG	(33)	(26)	(27)
INFLAMMATION, INTERSTITIAL	2 (6%)		
BRONCHOPNEUMONIA SUPPURATIVE	1 (3%)		
BRONCHOPNEUMONIA CHRONIC SUPPURA	9 (27%)		
HEMATOPOIETIC SYSTEM			
*BONE MARROW	(32)	(21)	(25)
ATROPHY, NOS	1 (3%)		
*SPLEEN	(34)	(20)	(26)
INFLAMMATION, NECROTIZING	1 (3%)		
HEMATOPOIESIS	4 (12%)	2 (10%)	3 (12%)
*MESENTERIC L. NODE	(26)	(20)	(23)
INFLAMMATION, NECROTIZING	1 (4%)		
INFLAMMATION, ACUTE SUPPURATIVE	1 (4%)		
HYPERPLASIA, LYMPHOID			1 (4%)
*INGUINAL LYMPH NODE	(26)	(20)	(23)
HYPERPLASIA, LYMPHOID		1 (5%)	
CIRCULATORY SYSTEM			
NONE			
* NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

TABLE D4. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

	LOW DOSE	MID DOSE	HIGH DOSE
DIGESTIVE SYSTEM			
#LIVER	(33)	(24)	(27)
INFLAMMATION, SUPPURATIVE	1 (3%)		
INFLAMMATION, NECROTIZING	1 (3%)		1 (4%)
NECROSIS, FOCAL		1 (4%)	
NECROSIS, COAGULATIVE		1 (4%)	3 (11%)
HEMATOPOIESIS	1 (3%)		
#HEPATIC CAPSULE	(33)	(24)	(27)
CALCIFICATION, DYSTROPHIC	1 (3%)		
#ESOPHAGUS	(29)	(20)	(24)
ULCER, NOS		6 (30%)	3 (13%)
INFLAMMATION, SUPPURATIVE	1 (3%)		
ULCER, CHRONIC		4 (20%)	
#STOMACH	(33)	(18)	(17)
ULCER, NOS	1 (3%)		
URINARY SYSTEM			
#URINARY BLADDER	(26)	(21)	(18)
INFLAMMATION, SUPPURATIVE			1 (6%)
ULCER, CHRONIC		1 (5%)	
ENDOCRINE SYSTEM			
NONE			
REPRODUCTIVE SYSTEM			
#UTERUS/ENDOMETRIUM	(29)	(22)	(25)
INFLAMMATION, SUPPURATIVE	1 (3%)		
INFLAMMATION, ACUTE/CHRONIC	1 (3%)		
HYPERPLASIA, CYSTIC	21 (72%)		
#OVARY	(21)	(19)	(24)
CYST, NOS		1 (5%)	
NERVOUS SYSTEM			
NONE			
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

TABLE D4. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)

	LDW DDSE	MID DDSE	HIGH DDSE
SPECIAL SENSE ORGANS			
NONE			
MUSCULOSKELETAL SYSTEM			
NONE			
BODY CAVITIES			
*PERITONEUM	(34)	(26)	(27)
INFLAMMATION, CHRONIC	13 (38%)	1 (4%)	
*VISCERAL PERITONEUM	(34)	(26)	(27)
INFLAMMATION, SUPPURATIVE			1 (4%)
INFLAMMATION, HEMORRHAGIC			1 (4%)
INFLAMMATION, CHRONIC		24 (92%)	14 (52%)
INFLAMMATION, CHRONIC NECROTIZIN			1 (4%)
*PLEURA	(34)	(26)	(27)
INFLAMMATION, SUPPURATIVE		4 (15%)	2 (7%)
INFLAMMATION, CHRONIC		2 (8%)	
ALL OTHER SYSTEMS			
NONE			
SPECIAL MORPHOLOGY SUMMARY			
NO LESION REPORTED	2		6
ANIMAL MISSING/NO NECROPSY		1	
NO NECROPSY PERFORMED	1		
AUTOLYSIS/NO NECROPSY		8	8
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

APPENDIX E

ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS IN
RATS TREATED WITH EMETINE

Table E1. Analyses of the Incidence of Primary Tumors in Male Rats
Treated with Emetine^a

<u>Topography: Morphology</u>	<u>Pooled Control</u>	<u>Vehicle Control</u>	<u>Low Dose</u>	<u>High Dose</u>
Subcutaneous Tissue: Fibromab	0/25 (0)	0/10 (0)	2/35 (6)	0/27 (0)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f				
Lower Limit			Infinite	--
Upper Limit			0.218	--
			Infinite	--
Relative Risk (Vehicle Control) ^f				
Lower Limit			Infinite	--
Upper Limit			0.093	--
			Infinite	--
Weeks to First Observed Tumor	--	--	75	--
Liver: Hepatocellular Adenoma ^b	0/25 (0)	0/10 (0)	2/35 (6)	0/27 (0)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f				
Lower Limit			Infinite	--
Upper Limit			0.218	--
			Infinite	--
Relative Risk (Vehicle Control) ^f				
Lower Limit			Infinite	--
Upper Limit			0.093	--
			Infinite	--
Weeks to First Observed Tumor	--	--	84	--

Table E1. Analyses of the Incidence of Primary Tumors in Male Rats
Treated with Emetine^a

(continued)		Pooled	Vehicle	Low	High
Topography:	Morphology	Control	Control	Dose	Dose
Pituitary: Chromophobe Carcinoma ^b		2/25 (8)	1/10 (10)	1/32 (3)	1/22 (5)
P Values ^{c,d}		N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f					
Lower Limit				0.391	0.568
Upper Limit				0.007	0.010
				7.098	10.110
Relative Risk (Vehicle Control) ^f				0.313	0.455
Lower Limit				0.004	0.006
Upper Limit				23.802	34.087
Weeks to First Observed Tumor		--	84	84	80
Pituitary: Chromophobe Adenoma or Carcinoma ^b		3/25 (12)	2/10 (20)	4/32 (13)	2/22 (9)
P Values ^{c,d}		N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f					
Lower Limit				1.042	0.758
Upper Limit				0.195	0.069
				6.533	5.976
Relative Risk (Vehicle Control) ^f				0.625	0.455
Lower Limit				0.114	0.040
Upper Limit				6.349	5.664
Weeks to First Observed Tumor		--	84	84	80

Table E1. Analyses of the Incidence of Primary Tumors in Male Rats
Treated with Emetine^a

(continued)						
<u>Topography: Morphology</u>	<u>Pooled Control</u>	<u>Vehicle Control</u>	<u>Low Dose</u>	<u>High Dose</u>		
Parathyroid: Adenoma, NOS ^b	0/9 (0)	0/4 (0)	0/10 (0)	1/7 (14)		
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.		
Relative Risk (Pooled Control) ^f						
Lower Limit			--	Infinite		
Upper Limit			--	0.076		
			--	Infinite		
Relative Risk (Vehicle Control) ^f						
Lower Limit			--	Infinite		
Upper Limit			--	0.039		
			--	Infinite		
Weeks to First Observed Tumor	--	--	--	83		
Pancreatic Islets:						
Islet-cell Adenoma ^b	0/24 (0)	0/9 (0)	2/34 (6)	1/26 (4)		
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.		
Relative Risk (Pooled Control) ^f						
Lower Limit			Infinite	Infinite		
Upper Limit			0.215	0.051		
			Infinite	Infinite		
Relative Risk (Vehicle Control) ^f						
Lower Limit			Infinite	Infinite		
Upper Limit			0.088	0.020		
			Infinite	Infinite		
Weeks to First Observed Tumor	--	--	84	83		

Table E1. Analyses of the Incidence of Primary Tumors in Male Rats Treated with Emetine^a

(continued)				
<u>Topography: Morphology</u>	<u>Pooled Control</u>	<u>Vehicle Control</u>	<u>Low Dose</u>	<u>High Dose</u>
Testis: Interstitial-cell Tumor ^b	0/25 (0)	0/10 (0)	3/34 (9)	0/27 (0)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Departure from Linear Trend ^e	P = 0.029			
Relative Risk (Pooled Control) ^f				
Lower Limit			Infinite	--
Upper Limit			0.453	--
			Infinite	--
Relative Risk (Vehicle Control) ^f				
Lower Limit			Infinite	--
Upper Limit			0.197	--
			Infinite	--
Weeks to First Observed Tumor	--	--	84	--

^aTreated groups received doses of 0.5 or 1 mg/kg body weight by intraperitoneal injection.

^bNumber of tumor-bearing animals/number of animals examined at site (percent).

^cBeneath the incidence of tumors in a control group is the probability level for the Cochran-Armitage test when $P < 0.05$; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the vehicle-control group (*) or with the pooled-control group (**) when $P < 0.05$ for either control group; otherwise, not significant (N.S.) is indicated.

Table E1. Analyses of the Incidence of Primary Tumors in Male Rats
Treated with Emetine^a

(continued)

^dA negative trend (N) indicates a lower incidence in a treated group than in a control group.

^eThe probability level for departure from linear trend is given when $P < 0.05$ for any comparison.

^fThe 95% confidence interval of the relative risk between each treated group and the specified control group.

Table E2. Analyses of the Incidence of Primary Tumors in Female Rats Treated with Emetine^a

<u>Topography: Morphology</u>	<u>Pooled Control</u>	<u>Vehicle Control</u>	<u>Low Dose</u>	<u>High Dose</u>
Pituitary: Chromophobe Carcinoma ^b	2/25 (8)	1/10 (10)	1/35 (3)	1/33 (3)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f				
Lower Limit			0.357	0.379
Upper Limit			0.006	0.007
			6.515	6.894
Relative Risk (Vehicle Control) ^f			0.286	0.303
Lower Limit			0.004	0.004
Upper Limit			21.825	23.104
Weeks to First Observed Tumor	--	84	84	84
Pituitary: Chromophobe Adenoma or Carcinoma ^b	9/25 (36)	4/10 (40)	12/35 (34)	9/33 (27)
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f				
Lower Limit			0.952	0.758
Upper Limit			0.445	0.320
			2.174	1.844
Relative Risk (Vehicle Control) ^f			0.857	0.682
Lower Limit			0.369	0.270
Upper Limit			3.071	2.563
Weeks to First Observed Tumor	--	84	84	61

Table E2. Analyses of the Incidence of Primary Tumors in Female Rats
Treated with Emetine^a

(continued)		Pooled Control	Vehicle Control	Low Dose	High Dose
Topography: Morphology					
Adrenal: Cortical Adenoma ^b		3/25 (12)	3/10 (30)	9/35 (26)	2/35 (6)
P Values ^{c,d}		N.S.	P = 0.018(N)	N.S.	N.S.
Departure from Linear Trend ^e		P = 0.026			
Relative Risk (Pooled Control) ^f					
Lower Limit				2.143	0.476
Upper Limit				0.608	0.043
				11.255	3.876
Relative Risk (Vehicle Control) ^f					
Lower Limit				0.857	0.190
Upper Limit				0.291	0.020
				4.323	1.494
Weeks to First Observed Tumor		--	84	66	84
Mammary Gland:					
Adenocarcinoma, NOS ^b		0/25 (0)	0/10 (0)	1/35 (3)	2/35 (6)
P Values ^{c,d}		N.S.	N.S.	N.S.	N.S.
Relative Risk (Pooled Control) ^f					
Lower Limit				Infinite	Infinite
Upper Limit				0.039	0.218
				Infinite	Infinite
Relative Risk (Vehicle Control) ^f					
Lower Limit				Infinite	Infinite
Upper Limit				0.017	0.093
				Infinite	Infinite
Weeks to First Observed Tumor		--	--	84	61

Table E2. Analyses of the Incidence of Primary Tumors in Female Rats
Treated with Emetine^a

(continued)						
Topography: Morphology	Pooled Control	Vehicle Control	Low Dose	High Dose		
Mammary Gland: Fibroadenoma ^b	5/25 (20)	2/10 (20)	14/35 (40)	10/35 (29)		
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.		
Relative Risk (Pooled Control) ^f						
Lower Limit			2.000	1.429		
Upper Limit			0.802	0.516		
			6.183	4.720		
Relative Risk (Vehicle Control) ^f						
Lower Limit			2.000	1.429		
Upper Limit			0.604	0.398		
			16.343	12.223		
Weeks to First Observed Tumor	--	84	66	52		
Uterus: Endometrial Stromal Polyp ^b	0/25 (0)	0/10 (0)	3/35 (9)	1/35 (3)		
P Values ^{c,d}	N.S.	N.S.	N.S.	N.S.		
Relative Risk (Pooled Control) ^f						
Lower Limit			Infinite	Infinite		
Upper Limit			0.443	0.039		
			Infinite	Infinite		
Relative Risk (Vehicle Control) ^f						
Lower Limit			Infinite	Infinite		
Upper Limit			0.191	0.017		
			Infinite	Infinite		
Weeks to First Observed Tumor	--	--	84	83		

Table E2. Analyses of the Incidence of Primary Tumors in Female Rats
Treated with Emetine^a

(continued)

^aTreated groups received doses of 0.5 or 1 mg/kg body weight by intraperitoneal injection.

^bNumber of tumor-bearing animals/number of animals examined at site (percent).

^cBeneath the incidence of tumors in a control group is the probability level for the Cochran-Armitage test when $P < 0.05$; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the vehicle-control group (*) or with the pooled-control group (**) when $P < 0.05$ for either control group; otherwise, not significant (N.S.) is indicated.

^dA negative trend (N) indicates a lower incidence in a treated group than in a control group.

^eThe probability level for departure from linear trend is given when $P < 0.05$ for any comparison.

^fThe 95% confidence interval of the relative risk between each treated group and the specified control group.

APPENDIX F

ANALYSES OF THE INCIDENCE OF PRIMARY TUMORS IN
MICE TREATED WITH EMETINE

Table F1. Analyses of the Incidence of Primary Tumors in Male Mice
Treated with Emetine^a

<u>Topography: Morphology</u>	<u>Vehicle Control</u>	<u>Low Dose</u>	<u>Mid Dose</u>	<u>High Dose</u>
Lung: Alveolar/Bronchiolar Adenoma ^b	1/24 (4)	2/35 (6)	0/28 (0)	0/29 (0)
P Values ^{c,d}	--	N.S.	N.S.	N.S.
Relative Risk (Vehicle Control) ^e				
Lower Limit		1.371	0.000	0.000
Upper Limit		0.076	0.000	0.000
		78.550	15.768	15.243
Weeks to First Observed Tumor	82	72	--	--
Lung: Alveolar/Bronchiolar Adenoma or Carcinoma ^b	1/24 (4)	3/35 (9)	0/28 (0)	0/29 (0)
P Values ^{c,d}	--	N.S.	N.S.	N.S.
Relative Risk (Vehicle Control) ^e				
Lower Limit		2.057	0.000	0.000
Upper Limit		0.180	0.000	0.000
		104.742	15.768	15.243
Weeks to First Observed Tumor	82	72	--	--

Table Fl. Analyses of the Incidence of Primary Tumors in Male Mice
Treated with Emetine^a

(continued)				
<u>Topography: Morphology</u>	<u>Vehicle Control</u>	<u>Low Dose</u>	<u>Mid Dose</u>	<u>High Dose</u>
Liver: Hepatocellular Carcinoma ^b	1/24 (4)	3/35 (9)	0/27 (0)	0/30 (0)
P Values ^{c,d}	--	N.S.	N.S.	N.S.
Relative Risk (Vehicle Control) ^e				
Lower Limit		2.057	0.000	0.000
Upper Limit		0.180	0.000	0.000
		104.742	16.331	14.750
Weeks to First Observed Tumor	75	50	--	--

^aTreated groups received doses of 1.6, 3.2, or 6.4 mg/kg body weights by intraperitoneal injection.

^bNumber of tumor-bearing animals/number of animals examined at site (percent).

^cBeneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the matched control group when $P < 0.05$; otherwise, not significant (N.S.) is indicated.

^dSince survivals were not comparable no trend tests were made.

^eThe 95% confidence interval of the relative risk between each treated group and the matched control group.

Table F2. Time-adjusted Analyses of the Incidence of Primary Tumors in Male Mice Treated with Emetine^a

<u>Topography: Morphology</u>	<u>Vehicle Control</u>	<u>Low Dose</u>	<u>Mid Dose</u>	<u>High Dose</u>
Lung: Alveolar/Bronchiolar Adenoma (52) ^b	1/23 (4)	2/30 (7)	0/2 (0)	0/1 (0)
P Values ^{c,d}	--	N.S.	N.S.	N.S.
Relative Risk (Vehicle Control) ^e		1.533	0.000	0.000
Lower Limit		0.085	0.000	0.000
Upper Limit		87.354	119.310	89.856
Weeks to First Observed Tumor	82	72	--	--
Lung: Alveolar/Bronchiolar Adenoma or Carcinoma (52) ^b	1/23 (4)	3/30 (10)	0/2 (0)	0/1 (0)
P Values ^{c,d}	--	N.S.	N.S.	N.S.
Relative Risk (Vehicle Control) ^e		2.300	0.000	0.000
Lower Limit		0.200	0.000	0.000
Upper Limit		116.430	119.310	89.856
Weeks to First Observed Tumor	82	72	--	--

Table F2. Time-adjusted Analyses of the Incidence of Primary Tumors in
Male Mice Treated with Emetine^a

(continued)				
<u>Topography: Morphology</u>	<u>Vehicle Control</u>	<u>Low Dose</u>	<u>Mid Dose</u>	<u>High Dose</u>
Liver: Hepatocellular Carcinoma (50) ^b	1/23 (4)	3/31 (10)	0/2 (0)	0/1 (0)
P Values ^{c,d}	--	N.S.	N.S.	N.S.
Relative Risk (Vehicle Control) ^e		2.226	0.000	0.000
Lower Limit		0.196	0.000	0.000
Upper Limit		112.848	119.310	89.856
Weeks to First Observed Tumor	75	50	--	--

^aTreated groups received doses of 1.6, 3.2, or 6.4 mg/kg body weight by intraperitoneal injection.

^bNumber of tumor-bearing animals/number of animals examined at site (percent), based upon animals that lived at least as long as the number of weeks on study shown in parentheses after the morphology.

^cBeneath the incidence of tumors in a treated group is the probability level for the Fisher exact test for the comparison of that treated group with the matched control group when $P < 0.05$; otherwise, not significant (N.S.) is indicated.

^dSince survivals were not comparable no trend tests were made.

^eThe 95% confidence interval of the relative risk between each treated group and the matched control group.

Review of the Bioassay of Emetine*for Carcinogenicity
by the Data Evaluation/Risk Assessment Subgroup of the
Clearinghouse on Environmental Carcinogens

November 28, 1977

The Clearinghouse on Environmental Carcinogens was established in May, 1976 under the authority of the National Cancer Act of 1971 (P.L. 92-218). The purpose of the Clearinghouse is to advise on the National Cancer Institute's bioassay program to identify and evaluate chemical carcinogens in the environment to which humans may be exposed. The members of the Clearinghouse have been drawn from academia, industry, organized labor, public interest groups, State health officials, and quasi-public health and research organizations. Members have been selected on the basis of their experience in carcinogenesis or related fields and, collectively, provide expertise in organic chemistry, biochemistry, biostatistics, toxicology, pathology, and epidemiology. Representatives of various Governmental agencies participate as ad hoc members. The Data Evaluation/Risk Assessment Subgroup of the Clearinghouse is charged with the responsibility of providing a peer review of NCI bioassay reports on chemicals studied for carcinogenicity. In this context, below is the edited excerpt from the minutes of the Subgroup's meeting at which Emetine was reviewed.

It was noted that the drug was tested as part of a program to study the potential carcinogenicity of cancer chemotherapeutic agents. The experimental protocol deviated from the standard bioassay, since it was meant to mimic the clinical exposure situation. The primary reviewer said that the high dose levels initially tested were excessive, as evidenced by the growth curves and mortality incidences. Although the NCI staff concluded that the study was inadequate to evaluate the carcinogenicity of Emetine, the Subgroup reviewer said that the survival was sufficient at low dosages to assess the drug when used as a chemotherapeutic agent in adults. He concluded that Emetine poses no carcinogenic hazard when used as an adult chemotherapeutic agent. He added that the study was inadequate as a carcinogenicity screen if the drug were to be used in children.

The secondary reviewer said that he agreed with the conclusions stated in the report. His assessment was based on the high mortality resulting in inadequate numbers of animals in each group. A discussion ensued as to the weight that should be given to a negative study that contained less than the desired number of animals. It was suggested by one Subgroup member that a probabilistic model be constructed that could be used for interpreting negative studies.

A motion was made as follows: "As part of a program of research on the potential carcinogenicity of drugs used in cancer chemotherapy, Emetine was tested in rats and mice. Survival of the mice was poor. The bioassay is inadequate to answer the question of carcinogenicity in the absolute sense, but the data obtained do not seem to indicate (Emetine to be) an appreciable risk when used in chemotherapy in adults. If (its) independent use is contemplated, more adequate data need to be developed for a definitive conclusion to be drawn." The motion was seconded and approved by all present except Mr. Garfinkel, who opposed it.

Members present were:

Gerald N. Wogan (Chairman), Massachusetts Institute of Technology
Lawrence Garfinkel, American Cancer Society
Henry C. Pitot, University of Wisconsin Medical Center
George Roush, Jr., Monsanto Company
Verald K. Rowe, Dow Chemical U.S.A.
Michael B. Shimkin, University of California at San Diego
Louise Strong, University of Texas Health Sciences Center
John H. Weisburger, American Health Foundation

-
- * Subsequent to this review, changes may have been made in the bioassay report either as a result of the review or other reasons. Thus, certain comments and criticisms reflected in thre review may no longer be appropriate.

Library
National Institutes of Health
Bethesda, Maryland 20914

[illegible]

<http://nihlibrary.nih.gov>

**10 Center Drive
Bethesda, MD 20892-1150
301-496-1080**



NIH LIBRARY



3 1496 00185 2709